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SUMMARY 
Regulatory T cells (Treg) offer new immunotherapeutic options to control undesired immune 
reactions, but the heterogeinetiy of Treg raises the question which Treg population should be 
used for clinical translation “from bench to bedside”, especially to solid organ transplantation 
(SOT) patients. Based on this final goal, this project involves three main parts: i) investigating 
Treg frequency and subsets distribution with age in healthy donors and transplant (Tx) 
patients; ii) comparing the suppressive capacity of Treg subsets and expanding them in vitro 
without losing functionality; iii) clarifyjing the differiation relationship of Treg subsets and 
their relation to conventional T cells (Tconv) by T cell receptor (TCR) repertoire analysis. 
  From both healthy donors and Tx patients, an age-dependent shift from naïve Treg (TregN) 
to memory Treg (TregM) was observed, dominated by the central-memory (CM) phenotype 
over less abundant effector-memory (EM) population; compared to age matched healthy 
donors, Treg in Tx patients contained less naive but more EM cells, moreover, they were pre-
activated by expression of CD137 due to the exposure to allo antigens, thus more susceptible 
to activation-induced cell death. Regarding control of early Tconv activation, TregCM showed 
enhanced suppressive capacity compared to TregN; furthermore, only TregCM could induce 
apoptosis of responder cells especially in NK cells and B cells populations while TregN could 
not, which may result from cell-cell interactions as TregM have mugh higher cytotoxic T-
lymphocyte antigen 4 (CTLA-4) expression than TregN. Following in vitro expansion of the 
Treg subsets with rapamycin, however, TregN converted mainly into TregCM phenotype with 
enhanced suppression activity comparable to the level of freshly isolated and expanded 
TregCM. The poor proliferation capacity of TregEM might indicate EM as the terminal 
differential stage. Expansion of Treg in the gas-permeable and GMP-compliant G-Rex device 
could further enhance the expansion without losing phenotype and functionality. These data 
suggest that expansion with total Treg is optimal for adoptive Treg therapy as the majority of 
them are the highly potent TregCM.  
  Lastly, TCR repertoire study by next generation sequencing (NGS) indicated that TregM 
derived from TregN rather than Tconv in an antigen-driven process. The highest similarity of 
the TCR repertoires was observed between TregCM and TregEM. These data reveal new 
insights for the first time into the distinct TCR repertoires of Treg subsets and Tconv in human 
by NGS technology.  
Zussamenfassung 
II 
 
ZUSAMMENFASSUNG  
Regulatorische T-Zellen (Treg) eröffnen neue immuntherapeutische Wege zur Kontrolle 
unerwünschter Immunreaktionen, jedoch wirft die Heterogenität dieser Zellen die Frage auf, 
welche Treg-Population für die klinische Anwendung im Rahmen der „bench to bedside“ -
Anwendung, besonders im Bereich der Organtransplantation, am geeignetsten erscheint. 
Darauf basierend werden in dieser Arbeit drei Fragestellungen bearbeitet: i) Bestimmung der 
Häufigkeit von Tregs und deren Subpopulationen in verschiedenen Altersgruppen bei 
Empfängern einer Organtransplantation (Tx) und einer gesunden Kontrollgruppe; ii) Vergleich 
der Suppressorkapazität verschiedener Treg-Populationen und in vitro-Expansion der Zellen 
unter Erhaltung ihrer Funktionalität; iii) Klärung der Differenzierungsmerkmale von Tregs 
und deren Verknüpfung mit konventionellen T-Zellen (Tconv) mittels Analyse des T-Zell-
Rezeptor- (TCR) Repertoires. 
  Sowohl bei gesunden Probanden als auch bei  Tx-Empfänger konnte eine altersabhängige 
Verschiebung von naiven (TregN) hin zu dominant zentralen Gedächtnis-Zellen (TregCM) 
beobachtet werden, Treg von Tx-Empfängern hatten mehr Effektor-Memory-Zellen (EM) und 
sie waren mehr aktiviert. In Bezug auf die Kontrolle der frühen Tconv zeigen TregCM eine 
erhöhte Suppressorkapazität im Vergleich zu TregN. Außerdem sind im Gegensatz zu TregN 
nur TregCM dazu in der Lage, Apoptose bei Responderzellen zu induzieren. Der Grund 
hierfür könnte in der stärkeren Expression von CTLA-4 auf TregM liegen. Die 
Expansionskultur führte zur phänotypischen  Veränderung der TregN, deren Umwandlung in 
TregCM mit einer verbesserten Suppressoraktivität verbunden ist, welche mit der von frisch 
isolierten und expandierten TregCM vergleichbar ist. Die schwache Proliferationskapazität 
der TregEM könnte die Effektor-Memory-Zellen als begrenzende Phase der 
Zelldifferenzierung ausweisen. Die Daten legen nahe, dass das Expandieren mit gesamt Treg 
für die Adoptive-Treg-Therapie optimal sind, da sie der größte Anteil von ihnen  die 
hochpotenten TregCM sind. 
  TCR-Studien mittels Next Generation Sequencing zeigen weiter, dass TregM aus TregN 
entstehen, anstatt aus Tconv, in einem Antigen-gesteuerten Prozess. Die größte Ähnlichkeit 
des TCR-Repertoires wurde hierbei zwischen TregCM- und TregEM-Zellen nachgewiesen. 
Diese Daten belegen erstmalig neue Erkenntnisse hinsichtlich der Unterschiede der TCR-
Repertoires von TregM und Tconv beim Menschen.  
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ABBREVIATIONS
ADCC antibody dependent cellular cytotoxicity 
APC     antigen presenting cells 
ATP                     adenosine triphosphate 
BCR B cell receptor 
BFA Brefeldin A 
cAMP                  cyclic adenosine monophosphate 
CD                       cluster of differentiation 
CDC complement dependent cytotoxicity  
cDNA complimentary DNA  
CDR3        the third complementarity-determining region 
CFSE                   arboxy fluorescein succinimidyl ester 
CTL                      cytotoxic T lymphocyte 
CTLA-4 Cytotoxic T-Lymphocyte Antigen 4 
DC                        dendritic cells 
FACS                     fluorescence activated cell sorting 
FCS                       fetal calf serum 
Foxp3                    forkhead box 3 
FSC forward scatter 
GVHD                   graft versus host disease 
hAB serum human serum AB 
HLA                      human leucocyte antigen 
HSCT                    hematopoetic stem cell transplantation 
IDO                         Indolamin-2,3-Dioxygenase 
IFN                            interferon 
IL                      interleukin 
iTreg              induced regulatory T cells 
IU international unit 
L/D LIVE/DEAD 
LFA-1 Lymphocyte function-associated antigen 1 
mAb                        monoclonal antibody 
MACS                     magnetic activated cell sorting 
MFI                        mean fluorescence intensity 
MH index Morisita-Horn similarity index  
MHC                         major histocompatibility complex 
NET neutrophils extracellular traps  
NFAT Nuclear factor of activated T-cells 
NF-ĸB   nuclear factor kappa-light-chain-enhancer of activated B cells 
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NGS  next generation sequencing 
NK cells                          natural killer cells 
nTreg                              natural regulator T cells 
OL overlap 
PBMC                           peripheral blood mononuclear cells 
PCR                              polymerase chain reaction 
PMA phorbol 12-myristate 13-acetate 
PRRs pattern recognition receptors  
SEM                         standard error mean 
SOT                         solid organ transplant 
SSC side scatter 
ST stimulated 
Tconv                 conventional T cells 
TconvM                       memory conventional T cells 
TconvN                   naïve conventional T cells 
TCR                        T-cell receptor 
TGF-ß                     tumor growth factor beta 
Th1                   type 1 T helper cells 
TLR Toll-like receptor 
TNF                     tumor necrosis factor 
Tr1                             type 1 regulatory T cells 
TregCM                   central memory Treg cells 
TregEM                     effector memory Treg cells 
TregM memory regulatory T cells 
TregN                         naïve regulatory T cells 
TSDR Treg specific demethylation region 
Tx transplantation 
UN un-stimulated 
V ß                          T-cell receptor variable ß chain 
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1. INTRODUCTION 
1.1 General aspects of Treg development and suppressive functionality 
1.1.1 Innate and adaptive immune system 
Human immune system is an extremely complex and powerful network, which functions like 
a strong army to protect us from infections. It can not only augment immune responses upon 
“foreign agents” like viruses; but also dampens reactions to “self-tissues”; resulting in a 
formidably active but homeostatic “protecting” environment. This powerful network consists 
of two distinct but intimately correlated systems: innate immune system and adaptive immune 
system.  
  Briefly, when we got infections, innate immune system firstly recognizes the conserved 
components in many microorganisms via pattern recognition receptors (PRRs), e.g. Toll-like 
receptors (TLR) and works immediately in a general manner by mainly phagocytosis and 
complement dependent cytotoxicity (CDC) (1-3). Leucocytes especially neutrophils, 
macrophages, dendritic cells, NK cells and mast T cells are involved in these processes. As 
the majority of phagocytes, neutrophils are one of the first “soldiers” arriving at an infection 
site under chemotaxis (4). On one hand, they kill the invading microbes directly by 
engulfment, secretion of anti-microbials and generation of neutrophils extracellular traps 
(NET) (5); on the other hand, neutrophils also secrete cytokines to recruit and activate other 
immune cells. In addition, macrophages present antigens to activate adaptive immune system 
like the big “presenter”, dendritic cells, but also produce many chemicals like enzymes to 
“digest” invading microbes directly (6).  
  However, innate immune system is far from enough for protecting organism from infections 
because lots of pathogens could escape it. Luckily, we got second the protection layer, 
adaptive immune system, which can be activated by innate immune responses thus “adapt” 
stronger responses and reinforce it when same antigens are met again by “memory” in a 
specific manner (7). Lymphocytes, especially B cells and T cells, are involved in these 
responses. On one hand, cytotoxic T cells can kill infected cells directly by releasing 
cytotoxins when they are activated by TCR binding to specific-antigen and MHC-I complex 
and CD8 molecule; on the other hand, helper T cells can recognize antigens with MHC-II 
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complex and get activated with releasing several cytokines to enhance the activity of 
macrophages and cytotoxic T cells for direct killing. Another big player in adaptive immune 
system is B cells(8). They recognize pathogens by their specific receptors on the cell surface 
and uptake and process it into many peptides, which are subsequently presented by these B 
cells with their MHC-II molecule to helper T cells, making these helper cells release 
cytokines and again stimulate B cells to become plasma cells producing large amount of 
antibody. These antibodies will again promote complement system by antibody-dependent 
cell mediated cytotoxicity (ADCC) or direct phagocytosis. In addition, some of activated T or 
B cells will become memory cells and response immediately next time when the same 
antigens were met (8). 
  The tight collaboration of innate and adaptive immune system provides a powerful network 
to protect us. More importantly, they can also discriminate “self” from “non-self” to minimize 
possible self-reactive damage in several ways. In brief, self-reactive clones in lymphocytes 
are neutralized mainly by clonal deletion, abortion and anergy when potential auto-reactive 
cells encounter antigens or by its regulatory mechanism when those cells escape thymus 
censorship (9, 10). In this regulatory mechanism, “suppressor T cells”, later called regulatory 
T cells (Treg), are proved to be one of the most important regulators in keeping immune 
homeostasis (11). 
1.1.2 General finding and development of Treg 
Treg are a specialized subpopulation of T cells that play a central role in maintaining 
homeostasis within immune system. The concept of suppressor T cells was raised in early 
1970s by Gershon and Kondo (12). They found that one population of T cells could not only 
enhance immune activity, but also suppress it, keeping immune responses more balanced. 
Massive researches regarding this T cell population, now called regulatory T cells, were 
conducted subsequently all over the world.  
  Like many other seminal findings in science, the exploration of Treg with significant 
importance in clinical adoptive cell therapy nowadays, also has ups and downs (13). From late 
1960s to early 1980s, Treg attracted much interest as the concept of the “suppressor T cells” 
was raised. During this period, it was found by many researchers that thymectomy of normal 
mice and rats produced damage in “self” organs like ovaries and led to the development of 
thyroiditis accompanied by autoantibodies production and so on (14-16). Type-1 diabetes was 
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also found to be induced with same methods in both mice and rats later (17, 18). More 
interestingly, inoculation of normal T cells from healthy mice or rats could prevent these 
autoimmune diseases in syngeneic animals (19, 20). Taken together, Sakaguchi et al.. 
proposed that the coexistence of potential self-reactive CD4 T cells mediating autoimmune 
diseases and other CD4 T cell population mainly suppressing them in periphery of healthy 
mice and rats (21).  
  From mid 1980s to early 1990s, research of suppressor T cells was hindered by the big issue 
regarding I-J region of mouse MHC gene and collapsed in this period. The I-J region was 
believed to encode important molecules expressed by suppressor T cells and pivotal to the 
suppression functionality (22). However, this region was not found in mouse MHC gene by 
molecular biology techniques (23), suggesting the previous concept of “suppressor T cells” 
might be false . Together with paucity of specific cell markers, research of suppressor T cells 
went downhill (13). 
  In the second half of the nineties, a milestone of suppressor T cells research was achieved 
mainly by the discovery of CD25, the α chain of interleukin 2 (IL2) receptor, which was 
found as a useful surface marker for the suppressive T cells, later called regulatory T cells 
(Treg) (24-26). Thus, Treg research was rising again with intensive further studies regarding 
the pivotal functional role of IL2 and CD25 for Treg survival (27-29). Furthermore, the 
discovery of CD25 also made isolation of Treg feasible, thus the investigation of Treg 
function in vivo with adoptive Treg cell transfer became achievable. 
  Since 2000s, massive investigations regarding Treg development and function have been 
conducted. Another mile stone was achieved by the discovery of transcriptional factor 
forkhead box P3 (FoxP3), also called Scurfin, as an important regulator for Treg development 
and function in 2003 (13). In the same year, several groups reported simultaneously that 
FoxP3 mRNA could be expressed by CD4+CD25+ peripheral T cells and CD4+CD8-CD25+ 
thymocytes, but not by CD4+CD25- conventional T cells; moreover, ectopic expression of 
Foxp3 conferred suppressor function on peripheral CD4+CD25- T cells (30-32). Later on, 
more and more data have proved that FoxP3 is a master controller of Treg development in 
thymus and function, thus the most reliable molecular Treg marker so far (33). Indentifying 
FoxP3 as the specific Treg marker further broadened the way nowadays for Treg research and 
benefited the clinical translation significantly as well. 
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1.1.3 Classification of thymus derived natural Treg and peripheral induced Treg 
Naturally occurring Treg (nTreg) derives in thymus. When a T cell precursor is produced in 
bone marrow and transferred into thymus, it will receive very strict “training” or “education” 
through several complicated selection processes. Only minority of the survivors can become 
final Treg cell and enter into periphery. To recognize millions of antigens presented by major 
histocompatibility complex (MHC) on the antigen-presenting cells, it is firstly essential for 
T cells to have enormous T cell receptor (TCR) repertoire which are mainly produced by 
stochastic V(D)J recombination of gene segments in the α and β chain of their TCR in the 
thymus as well as the random insertion and deletion of nucleotides at the segment junction 
sites. The clonal diversity of the TCR repertoire is further enhanced by different pairing of α 
and β chain. Subsequently, the whole repertoire is shaped by positive and negative selections. 
Positive selection selects single positive CD4 or CD8 T cells while negative selection further 
deletes the clones with high affinity to self peptide and MHC complexes (34). These two 
processes result in conventional T cells (Tconv) repertoire with low affinity to self-antigens 
but high-affinity to foreign antigens (35). Some self-reactive cells with intermediately high 
affinity can escape from negative selection and divert into nTreg cell lineage, which is mainly 
responsible for maintaining homeostasis within immune system. The lineage-specific 
transcription factor that determines the fate of Treg lineage is FoxP3 (36), its expression on 
developing thymocytes seems to depend chiefly on the intensity of TCR stimulation (37, 38). 
The demethylation of FoxP3 locus, Treg specific demethylation region (TSDR), depends on 
the duration of TCR stimulation, thus TSDR of nTreg are totally demethylated  (39). 
  Additionally, FoxP3+ Treg can also be induced from naïve Tconv with presence of cytokines 
and low amount of antigens in periphery (40-42), that is so-called induced Treg (iTreg). 
Unlike nTreg, TSDR of iTreg are not completely demethylated (43), although they also have 
FoxP3 expression. As nTreg mainly prevent autoimmunity to keep immune tolerance, iTreg 
are believed to mainly control chronic allergic inflammation and be one of the important 
barriers for tumor cells (43). Besides Th3 cells, CD4 typ1 regulatory T (Tr1) cells are another 
type of adaptive Treg produced out of thymus. They don’t express FoxP3, but secrete IL10 
and express granzyme B to kill myeloid antigen presenting cells (44, 45). The basic 
differentiation of different T cell lineages is shown in Figure 1. This project focuses on nTreg 
research. 
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Figure 1: Differentiation processes of different Treg and Tconv lineages. Each color represents one type of 
cells: Gray - T cell precursor; green - natural Treg; light yellow - naïve T cell; bright yellow – induced Treg; pink 
- Tconv.  
1.1.4 Treg Suppression mechanism  
Treg do the suppression job by several mechanisms. They can inhibit activation and 
proliferation of Tconv directly or indirectly via decreasing the antigen presentation ability of 
APCs (Figure 2). Firstly, Treg can secrete several immunosuppressive cytokines including 
TGFβ, IL10 and IL35, whose deficiency in mice could result in either autoimmunity or 
reduced suppressive activity (46, 47). Secondly, Treg can express granzyme and kill responder 
cells in perforin-dependent manner in human and mice (48, 49). Treg can also express 
Galectin-11, which is another important molecule during interaction of Treg-DC and Treg-
Tconv (50). Thirdly, Treg have higher expression of CD25, the α-chain of IL2 receptor, thus 
they compete IL2 with Tconv under certain conditions, resulting in suppression of Tconv 
activation and proliferation (51, 52).  
  From the anti-inflammatory aspect, Treg express ectoenzymes CD39 and CD73, which could 
hydrolyze extracellular ATP and AMP to produce the immunosuppressive molecule adenosine 
(53-55). Adenosine may inhibit DC and Tconv by increasing cyclic AMP (cAMP) through 
adenosine-A2A adenosine receptor signals (56, 57). cAMP is another key component of Treg 
mediated suppression as antagonism of cAMP could partly abrogate IL2 transcription and 
proliferation (58). Higher amount of cAMP in DC cocultured with Treg contributes to 
                                               
1 Galectin-1: a member of a highly conserved family of β-galactoside binding proteins. 
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suppression of DC in a mice model (59). Furthermore, cAMP in suppressed Tconv induces 
expression of the inducible cAMP early repressor (ICER), which acts as a repressor at IL2 and 
IL4 gene loci (60). Additionally, Treg suppress particular TCR signaling pathways in Tconv 
initially by suppression of calcium signaling, resulting in immediate inhibition of NFAT, NF-
ĸB  activation and then IL2 transcription (61). 
 
Figure 2: Different mechanisms of Treg-mediated Tconv suppression, adapted from Schmidt et al. (62). 
Treg have different suppression mechanisms under different situations. They can secrete inhibitory cytokines 
(TGFβ, IL10 and IL35) and kill Tconv by expressing granzymes in a perforin dependent manner. Treg also 
suppress Tconv proliferation by IL2 consumption due to higher amount of CD25 expression. Treg can rapidly 
suppress TCR-induced Ca2+, NFAT and NF-ĸB signal pathway. Treg can produce immunosuppressive molecule 
adenosine and transfer cAMP to Tconv or APCs. Furthermore, they can decrease antigen presentation ability of 
APCs via higher expression of CTLA-4. 
  Regarding antigen presenting cells (APC), Treg also suppress Tconv in an indirect manner 
by inhibiting the antigen presentation ability of APC. Both murine and human Treg express 
high amount of inhibitory molecule CTLA4 2  (63, 64), which compete for binding to 
CD80/CD86 with costimulatory molecule CD28 partly depending on adhesion molecule LFA-
13, thus decrease the cell-cell contact between Tconv and APCs in vitro and in vivo (65-68). 
On the other hand, Treg can also increase the expression of the enzyme indoleamine 2, 3-
dioxygenase (IDO) in DC via CTLA-4 induced signaling, resulting in starvation of Tconv and 
                                               
2 CTLA4: Cytotoxic T-Lymphocyte Antigen 4, also known as CD152. 
3 LFA-1: Lymphocyte function-associated antigen 1. 
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arrest of cell cycle, as IDO can catalyze degradation of the essential amino acid, tryptophan 
and also induce iTreg generation (69, 70). 
1.1.5 Cross talk between Treg and non-T cells 
In addition to the suppression of Tconv, Treg also interact with many other cell types 
including DC, B cells, NK cells, macrophages, osteoblasts, mast cells and NK T cells (71). 
Most importantly, Treg can decrease antigen presentation ability of DC as described 
previously. Additionally, it is reported that Treg derived from the tumor environment are able 
to lyse NK cells and CTL 4 in the granzyme B and perforin dependent manner (72). Recently, 
Gasteiger et al. found that restraint of NK cell cytotoxicity by Treg is related with limiting of 
IL2 availability (73). CD8 Treg have also been reported that they can down regulate the 
immune responses of macrophages in mice and human (74, 75). Regarding bone cells, Treg 
have been shown that they could suppress osteoclasts differentiation by secretion of cytokines 
like TGF-β in vitro in 2007 (76, 77). Several years later, protection of local and systematic 
bone destruction by Treg was observed as well in vivo by the same authors (78, 79), indicating 
further crosstalk between skeletal system and immune system. Regarding B cells, although 
they might be affected by immune suppressive cytokines secreted by Treg, it’s not clear so far 
whether Treg are able to induce apoptosis or cell death of B cells in human. 
1.2 Heterogeneous Treg for clinical translation 
1.2.1 Treg for adoptive cell therapy 
Since the discovery of CD25 as a new Treg surface marker in 1995 (24), worldwide 
substantial efforts have been made in understanding the mechanism of Treg suppression and 
exploring related clinical application for cellular therapy. Data from animal models have 
proved that adoptive transfer of Treg can prevent several autoimmune diseases and block 
GvHD 5  and allograft rejection after transplantation (80, 81). Therefore, regarding the 
essential role of Treg in keeping immune tolerance, there are several different translational 
therapy strategies from different aspects, as shown in Figure 3(82).   
                                               
4 CTL: Cytotoxic T Lymphocyte, also known as CD8+ T cell or killer T cell 
5 GvHD: Graft versus Host Diease. 
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Figure 3: Treg immunotherapy, adapted from Wang et al. (82).  
  In vivo targeting of Treg for therapy has two aspects: i) in vivo depletion of Treg could be 
used for treatment of cancer and chronic infection by injection of diphtheria toxin-IL-2 fusion 
protein, which can bind to CD25, internalize cells (mostly Treg) and kill these cells, resulting 
in augmenting anti-tumor and anti-viral function of Tconv (bottom left in Figure 3Figure 3) 
(83); ii) in vivo activation and expansion of Treg with depletion or inhibition of Tconv by 
using of rapamycin or CTLA-4-Ig fusion protein could induce tolerance to allograft  and 
reduce several autoimmune diseases (top left in Figure 3) (84). However, regarding adoptive 
cellular therapy, nTreg can be isolated from peripheral blood, expanded in vitro to large 
numbers with keeping the phenotype and suppression activity, then infused back to the 
patients (top right in Figure 3); alternatively, due to the induction of Treg from naïve Tconv, 
naïve Tconv could also be isolated and induced into iTreg in vitro, then expanded to large cell 
numbers with keeping immunosuppressive capacity and infused back to patients, leading to 
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the final tolerance to allograft or reduce autoimmune responses (bottom right in Figure 3) 
(82).  
  So far, several proof of concept clinical studies on adoptive transfer of different Treg 
population have been conducted after allergenic bone marrow transplantation, which have 
proved that adoptive Treg therapy is safe and effective to treat several diseases (85-88). 
However, regarding more clinical relevance in autoimmune diseases like type-1 diabetes and 
solid organ transplantation (SOT), more new clinical trials are on the ways. Currently, we and 
other five European institutions are collaborating on the “ONE study” to translate adoptive 
Treg therapy into kidney transplantation. Thus, as Leslie et al. have proposed, Treg therapy 
may “get their chance to shine” and achieve a new exciting milestone for human immune 
tolerance induction in the future (89).  
1.2.2 nTreg heterogeneity in periphery 
Despite the promising prospect of Treg for adoptive cell therapy, there are still lots of open 
questions regarding Treg heterogeneity and stability for real clinical translation. Similar with 
Tconv, Treg also consist of naïve and memory sub-populations according to the expression of 
CD45RA (90, 91). Furthermore, according to the report from Sakaguchi group, nTreg could 
be divided into 3 subsets: CD45RA+Foxp3lo resting Treg (rTreg) and CD45RA–Foxp3hi 
effector Treg (eTreg) and CD45RA-Foxp3lo cells, since rTreg and eTreg are 
immunosuppressive in vitro but CD45RA-Foxp3lo cells are not, they are regarded as non-Treg, 
also due to their secretion of IL17, IL2 and IFN-γ. Interestingly, rTreg can convent into eTreg 
after T cell receptor (TCR) stimulation, but eTreg are more prone to apoptosis (92). In mice, 
FoxP3 expression in Treg are proved to be unstable in vivo, they may even get lost due to 
epigenetic modifications of the gene, thus these “unstable” Treg could differentiate into 
memory effector cells as a huge “danger” for potential adoptive Treg transfer (93), which 
makes Treg cell therapy even more complicated.  
  Regarding stability of Treg, Edinger group suggested naïve Treg as the most stable subset for 
adoptive Treg therapy as they could keep FoxP3 expression after strong and repeated TCR 
stimulation during in vitro expansion (94). However, majority of Treg express the “memory” 
phenotype, particularly in patients. This raises the question: which Treg subset should be used 
for adoptive cellular therapy with Treg in SOT patients? Thus, to translate Treg “from bench 
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to bedside”, it is pivotal to investigate the heterogeneous composition of Treg population and 
their functionality including stability more into details. 
1.2.3 In vitro isolation and expansion of nTreg 
Natural Treg are hypo-proliferative in vitro while Tconv are not, thus expansion of pure nTreg 
population to large numbers with keeping FoxP3 expression and suppression function is the 
biggest obstacle for clinical translation. Regarding isolation of pure nTreg, the discovery of 
CD25 made the isolation feasible and the involvement of CD127 enhanced the purity 
significantly. This is due to CD127 expression is inversely correlates with FoxP3 expression 
and Treg suppressive capacity. Therefore, sorting of CD4+CD25hiCD127lo cells becomes 
another isolation strategy for Treg (95). Except from the commonly used isolation methods 
like activated cell separation (MACS) and Fluorescence Activated Cell Sorting (FACS), IBA 
GmbH (Goettingen, Germany) has manufactured streptamer® reagents, including anti-CD4-
Fab-Streptamer, anti-CD25-Fab-Streptamer and anti-CD45RA-Fab-Streptamer, for isolation 
of Treg by several labeling and positive selection processes. After each selection, tagged cells 
are liberated from the magnetically tagged Fab-Streptamers by incubation with D-biotin, 
which is a competing Streptactin ligand and can cause dissociation of the Fab-Streptamer 
label from the cell surface. This isolation method provides a new option for Treg isolation 
(81).  
  Expansion of Treg in vitro without losing their phenotype and immune suppressive capacity 
is also essential for successful adoptive Treg therapy due to the low number of circulating 
Treg in periphery. From our data, only 0.5-1% total peripheral blood mononuclear cells 
(PBMC) are Treg by expressing the phenotype “CD4+CD25hiFoxP3+CD127lo” (Results 4.1.1). 
Several groups have proved that culturing  nTreg in vitro with anti-CD3 and anti-CD28 
monoclonal antibody-coated beads and high dose of IL-2 in presence of rapamycin can 
successfully expand them keeping high purity and suppression function (96, 97). However, 
since FoxP3 expression may get lost after strong and repeated stimulation during expansion 
(94), new strategy of Treg expansion with moderate stimulation conditions or in more 
effective cell culture devices are required for the future Treg expansion.  
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1.3 T cell receptor repertoire of Treg and Tconv 
1.3.1 T cell receptor (TCR) repertoire analysis methods 
As mentioned in 1.1.3, due to several selection processes, the T cell receptor (TCR) repertoire 
is highly diverse, 2.5×107 for human naïve T cells (98). To analyze such huge and diverse 
TCR repertoire, the conventional methods are mainly focused on measuring the length of the 
third complementarity-determining region (CDR3), the most variable region of TCRβ-chain 
(99). This analysis method includes several molecular and biological techniques. 
Complimentary DNA (cDNA) is generated from isolated RNA through reverse transcription 
process. CDR3-encoding mRNA are then amplified by PCR using specific V and C primers 
with combination of either fluorescent C or J primer or others like radiographic isotope. The 
product are later separated by electrophoresis and visualized by, for instance, fluorescent 
sequencing equipment. Bands of different fluorescence intensity pattern are finally observed, 
indicating total population of CDR3-encoding mRNA sharing same V-gene or V-J gene but 
with different length (100). Thus, analysis of CDR3 length distribution provides a basic 
perception of repertoire variations between different sub-populations and over time. It has 
been widely used in understanding the diversity of TCR repertoire in different cell types and 
at different infection periods (101-103).  
  Although we could get basic interpretation of TCR repertoire composition of a cell 
population by analysis of CDR3 length distribution, the specific clone information at a 
sequence level is still missing. Therefore, a new and more powerful technology named next 
generation sequencing (NGS) is generated and applied to analysis TCR repertoire at a 
sequence level in this century, which provides us the opportunity to simultaneously analyze 
single-gene disorders (104, 105). 
1.3.2 Treg subsets and Tconv TCR repertoire in mice and human 
In addition to the essential role in clinical diagnosis and monitoring during infections, TCR 
repertoire analysis is also important in studying development of distinct cell lineages and 
differential status of one specific cell type. Regarding T cells development, in accord with 
positive and negative selection processes in thymus, several groups have showed TCR 
repertoire of murine nTreg and Tconv are mostly distinct (106-108). Hindley et al. have 
analyzed  TCR repertoire of tumor-infiltrating Tconv and nTreg from mice and found no 
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overlap between them, indicating nTreg and Tconv TCR repertoire are influenced differently 
even in the same tumor microenvironment (107); Relland et al. have also found that TCR 
repertoire of nTreg and Tconv for same foreign antigen are distinct using CDR3 length 
distribution analysis by TCR α-chain spectratyping in mice (108). Interestingly, our group 
have found formerly that antigen specific iTreg and Tconv do share same clones for their TCR 
repertoire, indicating same origins of iTreg as Tconv, but distinct as nTreg (109). However, 
TCR data from human nTreg and Tconv are very limited (110), and no data has been available 
so far using next-generation sequencing. Regarding differential relations of several Treg 
subsets including naïve and memory cells, TCR repertoire data are also missing. 
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2. AIMS OF THIS WORK 
Due to the promising immune tolerance induction by Treg in several animal models (111-115) 
and the safety confirmation of Treg therapy in human (85), adoptive cellular therapy with 
Treg to solid organ transplantation patients (SOT patients) is the final goal of this project. 
However, to achieve this, more knowledge of Treg cell product composition and function is 
still needed. Recently, the existence of naïve and memory cells in natural Treg population has 
been shown and naïve Treg showed superior or equivalent capacity regarding in vitro 
expansion and suppression activity to memory Treg (90, 94). However, majority of Treg 
express the “memory” phenotype, particularly in SOT patients. This raises the question which 
Treg subset should be used. Thus, to translate Treg “from bench to bedside”, it is pivotal to 
investigate the heterogeneous composition of Treg population and their functionality with 
differentiation relationship. Therefore, three main topics should be addressed in this study: 
i. Study the heterogeneous composition of Treg in healthy donors and Tx patients. 
 Define total Treg population and subset composition from healthy donors based on age 
and gender 
 Compare subsets composition and correlations in Treg versus Tconv 
 Compare activation patterns of Treg and Tconv subsets upon in vitro TCR-stimulation 
 Compare subsets distribution and activation pattern of Treg in renal transplantation 
recipients with healthy donors 
ii. Compare the functional difference of Treg subsets. 
 Compare suppression activity of Treg subsets regarding activation, proliferation and 
apoptosis induction of responder cells 
 Study the cross talk between Treg subset and other immune cells 
 Impact of expansion on Treg subsets 
iii. Analyze the relationship of Treg subsets with Tconv using TCR repertoire analysis. 
 Study the differentiation relationship of Treg subsets  
 Study the relationship of Treg and Tconv by TCR repertoire  
These data that are of importance to decide whether we can use total Treg cell preparation, 
composed of different subset, or enrichment of particular Treg subset (e.g. naïve cells), are 
required for optimal adoptive Treg therapy in SOT patients. The TCR repertoire data of this 
study will shed light on differentiation relationship of human nTreg subsets and Tconv. 
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3. MATERIAL & METHODS 
3.1 Materials 
3.1.1 Subjects 
Blood samples for Treg phenotypic analysis were collected from healthy donors and renal 
transplant recipients (Tx patients) after getting written informed consent and approval by the 
Charité University Medicine Berlin ethics committee (Institutional Review Board). For the 
study of functionality and TCR repertoires, buffy coat samples of healthy adults from the 
German Red Cross (DRK) were used. 
3.1.2 Equipments and devices 
Table 1: List of main equipments and devices 
Equipment and Device  Company 
Flow Cytometer, FACS LSRII  BD Bioscience 
FACS (Cell-Sorter), FACSAria BD 
Quadro MACSTM Separation Unit 
Octo MACSTM Separation Unit 
MACSiMAG Separator 
 Miltenyi Biotec 
  
Cell counter CASY® Innovatis 
CO2 Incubator Sanyo 
G-Rex10 gas permeable culture device Wilson Wolf Manufacturing Corporation, USA 
FACS-Diva Software BD BioScience 
FlowJo Tree Star 
GraphPad Prism GraphPad Software 
3.1.3 Medias, Buffers and Solutions 
Table 2: List of Medias, buffers and solutions 
Medium or Buffer Description 
RMPI medium: 
 
Rosewell Park Memorial Institute Medium 
(RPMI) 1640 (Gibco BRL, USA), supplemented 
with 100 U/mL penicillin and 0.1 mg/ml 
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streptomycin and either 10% human AB serum 
(Lonza, USA) or 10% foetal calf serum (FCS, 
Sigma Aldrich, Germany) 
Proleukin medium X-Vivo 15 Medium, supplemented with 10% 
human AB Serum (Lonza, USA) and 500 IU/mL 
Proleukin with or without 100nm rapamycin 
PBS/BSA-buffer: 0.5% Bovine serum albumin (BSA Boehringer-
Mannheim, Germany) in PBS-buffer 
MACS buffer 2 mM ethylene diaminetetraacetic acid (EDTA) in 
PBS/BSA buffer 
FACS buffer 2 mM ethylene diaminetetraacetic acid (EDTA) in 
PBS/BSA buffer with 0.1% sodium azide 
Fix/Permeabilization buffer for intracellular 
staining  
eBioscience 
Annexin V binding buffer Biolegend 
 
3.1.4 Chemicals and Reagents 
Table 3: List of chemicals and reagents 
Chemical or reagent Company 
Brefeldin A (Bref-A), (5mg/ml in 70% ethanol) Sigma-Aldrich, Germany 
Carboxyfluoresceindiacetat (CFDA), 5mM in 
Dimethylsulfoxid (DMSO) 
Molecular Probes, Netherlands 
Monensin BD Bioscience, Germany 
EDTA , (2mM in PBS-Buffer) Merck, Germany 
4,6-Diamidin-2-Phenylindol-Dihydrochlorid 
(DAPI), (1g/ml in PBS-Buffer) 
Roche, Germany 
Paraformaldehyde (PFA) Sigma Aldrich, Schnelldorf 
Phorbol 12-Myristat 13-Acetat (PMA) Sigma Aldrich, Schnelldorf 
Ionomycin Sigma Aldrich, Schnelldorf 
Rapamycin Alexis Biochemicals 
3.1.5 Isolation and stimulation Kits 
Table 4: List of isolation and stimulation kits 
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Name of Kit Company 
CD4+CD25+ regulatory T cell Isolation Kit MiltenyiBiotec 
CD4+CD127dim/- regulatory T cell Isolation Kit MiltenyiBiotec 
CD4+CD45RA+ regulatory T cell Isolation Kit MiltenyiBiotec 
T cell Activation/ Expansion kit MiltenyiBiotec 
Treg Expansion Kit MiltenyiBiotec 
Human CD4 micro beads MiltenyiBiotec 
LIVE/DEAD Fixable Aqua dead cell staining kit Invitrogen 
QIAamp DNA Mini Kit Qiagen, Germany 
QIAamp DNA Micro Kit Qiagen, Germany 
Treg suppression inspector MiltenyiBiotec 
Fast Immune Human Regulatory T Cell Function 
Kit 
BD 
3.1.6 Antibodies 
Table 5: List of used antibodies 
Antibody (Clone) Conjugate Company 
CD14 (MHCD1430) Pacific Orange Invitrogen 
CD3 (UCHT1) PE-Cy7 BD BioScience 
CD3 (SK7) Pacific Blue BD BioScience 
CD4 (RPA-T4) Alexa 700 BD BioScience 
CD8 (APC-Cy7) SK1 BD BioScience 
CD25 (M-A251) PE BD BioScience 
CD127 (eBioRDR5) APC-eFlour 780 eBioScience 
FoxP3 (259D/C7) Alexa 488 BD BioScience 
Mouse IgG1 k ( MOPC-21) Alexa 488 BD BioScience 
Helios (22F6) Alexa 647 BioLegend 
CD45RA  (2H4LDH11LDB9) ECD Beckman Coulter, Krefeld 
CD45RO (APC) UCHL1 BD BioScience 
CD49d (MZ18-24A9) APC MiltenyiBiotech 
CD62L (DREG-56) PerCP-Cy5.5 BioLegend 
CD31 (WM59) PE-Cy7 BioLegend 
CD152, CTLA-4 (BNI3) PE-Cy5 BD BioScience 
CD154 (CD40L) (24-31) Pacific Blue BioLegend 
CD137 (4-1BB) PE-Cy5 BD BioScience 
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Annexin V Alexa 647 Biolegend 
IFNγ (4S. B3) APC Cy7 Biolegend 
IL-10 (JES3 19F1) PE BD BioScience 
IL-17 (BL168) Pacific Blue Biolegend 
IL-2 (MQ1-17H12) PerCP-Cy5.5 BD BioScience 
IL4 (8D4-8) PE BioLegend 
TNFα (MAb11) PE-Cy7 BioLegend 
FoxP3 (259D/C7) Alexa 488 BD BioScience 
Mouse IgG1 k ( MOPC-21) Alexa 488 BD BioScience 
Helios (22F6) Alexa 647 BioLegend 
CD45RA  (2H4LDH11LDB9) ECD Beckman Coulter, Krefeld 
CD45RO (APC) UCHL1 BD BioScience 
CD49d (MZ18-24A9) APC MiltenyiBiotech 
3.2 Methods 
3.2.1 PBMC isolation 
Peripheral blood mononuclear cells (PBMC) were separated from erythrocytes, granulocytes 
and plasma in whole blood using density gradient centrifugation with Biocoll. First, fresh 
heparin blood was diluted 1:1 by PBS; diluted blood was added carefully to Biocoll solution 
with a ratio of 2:1. Centrifugation was performed with 340 × g for 30 minutes at room 
temperature (RT) without brake. Due to different density of different cells, erythrocytes and 
granulocytes, PBMC were enriched to the interface between plasma (upper layer with 
thrombocytes) and Biocoll (Granulocytes and erythrocytes were under Biocoll), which were 
then transferred carefully into a new tube and washed with 50 ml PBS (340 × g, RT, 30 min). 
Cell pellets were re-suspended in another 50ml PBS and centrifuged again together with 
supernatant from the last wash. Lastly, cell pellets of one donor from all tubes were pooled 
and re-suspend in PBS. Subsequent cell counting was performed with CASY® cell counter 
according to the manual.     
  PBMC isolation from Buffycoat was performed in a shorter procedure. One Buffycoat 
(around 80-100ml) was put into 4 50ml-tubes evenly and added PBS to a final 35ml in each 
tube. This diluted blood was transferred subsequently to cover 15 ml Biocoll in a new tube 
with care. Centrifugation was done at 800 × g for 20 minutes at room temperature (RT) 
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without brake. Cells in the interface were transferred and washed twice afterwards as 
described before. 
3.2.2 Flow cytometric staining and analysis 
Flow cytometric staining contains surface staining for cell surface molecules and intracellular 
staining for transcription markers and cytokines. For the surface staining, 250 µl whole blood 
or 106 PBMCs were put in a 5ml FACS-tube and washed twice with 1ml PBS/BSA buffer 
(4°C, 340 × g, 6 min). Discard supernatant and re-suspend cells in 50 µl staining buffer. 
Fluorescent dyes conjugated antibodies for surface markers were mixed with staining buffer 
to a final volume of 50 µl per sample, which was added to each tube, mixed, and incubated 
with cells on ice for 20 minutes away from light. Wash the cells with 1 ml FACS buffer (4 °C, 
340 × g, 6 min), discard supernatant and re-suspend cells in around 100 µl buffer, which were 
either analysed on flow cytometry (LSR II) immediately or fixed and permeabilized for 
intracellular staining.  
  Intracellular staining was done mainly by the Foxp3 staining protocol from eBioscience. 
Briefly, after surface staining, cells were fixed with 1 ml freshly prepared Fix/Perm buffer 
(Dilute Fix/Perm concentrate to 1:4 with Fix/Perm dilution buffer), vertex and incubate at 
room temperature for 30 min away from light. Cells were washed once with FACS buffer 
first, then twice with permeabilizaiton buffer (Dilute 10× concentrate to 1:10 with water). 
Prepare 50 µl antibodies mixture to each sample for intracellular staining with diluted 
permeabilizaiton buffer. Add 50 µl antibodies mixture to each tube and make a final 100 µl 
volume for staining at room temperature for 30-60 min away from light. Cells were 
subsequently washed with 1 ml diluted permeabilizaiton buffer and re-suspended in 100 µl 
buffer. Flow cytometric analysis was performed afterwards on LSR II with FACS DIVA 
software. 
  Due to potential influence of Ficoll separation, we compared the staining with the fresh 
whole blood and the Ficoll-isolated PBMC for Treg phenotype, gating strategy is shown in 
Figure 4. Firstly, dead cells and monocytes were excluded by Live/Dead aqua and CD14 
together in a dump channel. Secondly, we gated roughly on lymphocyte population by 
forward scatter (FSC) and side scatter (SSC), doublets were excluded further by FSC-A and 
FSC-H. T cells were gated as CD3+ cells and CD4 T cells as CD3+CD4+ cells. To obtain pure 
Treg population, we used CD127 for further gating and defined Treg as 
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CD4+CD25hiFoxP3+CD127lo cells, CD127lo cells on total live PBMC was used as a template 
for gating. Staining between whole blood and PBMC were comparable; however, for 
intracellular FoxP3 staining, the positive population was clearer from PBMC staining 
compared to whole blood (Figure 4) 
 
Figure 4: Phenotypic staining of total Treg in fresh whole blood and PBMC. Stepwise phenotypic gating 
strategy was showed in fresh whole blood and PBMC from one representative donor. 
3.2.2.1 FACS panel for Treg phenotypes 
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Table 6: Antibodies mixture for one sample 
Panel 1: Surface staining AB [μl] Panel 2: Surface staining AB [μl] 
L/D (PO) 0.5 CD14 (PO)  5 
CD3 (PECy7) 4 L/D (PO) 0.5 
CD4 (Alexa 700) 2 CD3 (PB) 4 
CD25 (PE)  5 CD4 (Alexa 700) 2 
CD127 (APC-Alexa 780) 2 CD25 (PE) 5 
CD49d (APC)  2 CD127 (APC-Alexa 780) 3 
CD45RA (ECD)  2 CD45RA (ECD) 2 
/ / CD31 (PeCy7)   5 
/ / CD62L (PerCP-Cy5.5) 1 
Intracellular staining AB [μl] Intracellular staining AB [μl] 
Foxp3 (A488) 10 Foxp3 (A488) 10 
CTLA-4 (PE-Cy5) 3 Helios (A647) 5 
3.2.2.2 FACS panel for Treg activation 
Cells were stimulated with CD2/3/28 T cell activation beads with a ratio of 1 cell to 1 bead for 
24 hours. After initiating the stimulation for 2 hours, 3µg/ml Brefeldin A was added.  
Table 7: Antibodies for Treg activation panel 
Surface staining AB [μl] 
L/D (PO) 0.5 
CD3 (PECy7) 4 
CD4 (Alexa 700) 2 
CD25 (PE)  5 
CD127 (APC-Alexa 780) 2 
CD49d (APC)  2 
CD45RA (ECD)  2 
Intracellular staining AB [μl] 
Foxp3 (A488) 10 
CD137 (PE-Cy5) 5 
CD154 (PB) 1 
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3.2.2.3 FACS panel for cytokines 
Cells were stimulated with 50ng/ml PMA and 600ng/ml Ionomycin for 6 hours, the last 4 
hours were accompanied by 2µM Monensin and 7.5µg/ml Brefeldin A.  
Table 8: Antibodies for cytokines 
Surface staining AB [μl] 
L/D (PO) 0.5 
CD4 (ECD)  3 
Intracellular staining AB [μl] 
Foxp3 (A488) 10 
Helios (A647) 5 
IL2 (PerCP-Cy5.5) 4 
IL10 (PE) 10 
IL17 (PB) 2 
IFNg (Alexa 700) 1 
TNFa (Pe-Cy7) 0.5 
IL2 (PerCP-Cy5.5) 4 
3.2.3 Fluorescence Activated Cell Sorting (FACS) 
PBMC were first sorted for CD4 T cells by positive selection with magnetic activated cell 
separation (MACS). Briefly, cells were washed with 10 ml MACS buffer twice, discard 
supernatant, then 200 µl human CD4 microbeads were added to 800 µl cells suspension (1: 5), 
vortex and incubate in the fridge for 15 minutes, then wash them once. Transfer cells from 
one buffy coat to 2 pre-rinsed LS columns; wash them for 3 times with 3ml MACS buffer. 
Lastly, the columns were taken out of magnet and put on new Falcon tubes; each column was 
immediately eluted with 5 ml MACS buffer. Merge eluate from one donor together and 
centrifuge the cells, i.e., CD4+ fraction. 
  108 MACS sorted CD4+ T cells were stained with 15µl CD4 (Alexa 700), 50µl CD25 (PE), 
50µl CD45RA (FITC) and 10µl CD62L (PerCP_Cy5.5) in a final 1ml buffer for 20 minutes in 
the fridge. Cells were washed and filtered.  DAPI was added to cell suspension before sorting 
with ratio of 3:100. CD4+CD25- fraction was sorted as Tconv; CD4+CD25hiCD45RA+ fraction 
was sorted as naïve Treg; memory counterpart as CD4+CD25hiCD45RA- cells were further 
separated into CD62L+ (central memory) and CD62L- (effector memory) fractions. 
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3.2.4 FoxP3 demethylation assay 
The FoxP3 demethylation assay was performed mainly as described before with minor 
modification (116, 117). Briefly, Genomic DNA of Treg and Tconv subsets were extracted 
with QIAamp DNA Blood Mini Kit (Qiagen, Germany) and performed for bisulfate 
conversion subsequently according to the manual (EpiTect, Qiagen). Generally, 60ng 
bisulfate-treated DNA were used for real-time PCR in a final volume of 20 µl containing 
FastStart Universal Probe Master, Lamda DNA, methylation or non-methylation-specific 
probe and primers from Epiontis Company. When more bisulfate-treated DNA (maximal 
240ng) was added, the final volume of reaction was also scaled up with the same 
concentration of other reagents. Final proportion of demethylated FoxP3 locus of TSDR was 
calculated by dividing the demethylated copy number by the total genomic FoxP3 copy 
number.   
3.2.5 Treg functional assay 
3.2.5.1 Suppression assay of activation 
The suppression assay was mainly performed as published previously with minor 
modifications (118). Briefly, 105 autologous PBMC were used as responder cells; they were 
cultured either alone or with 2.5×104 or 105 Treg, final volume in each well was adjusted to 
200µl with RMPI medium. CD2/3/28 beads were added into each well with a ratio of 1 cell to 
1 bead. Lastly, add 3µl CD154APC to each well to stain transiently expressed CD154 on cell 
surface. The whole 96-well plate was centrifuged shortly at room temperature with 500 ×g for 
1 minute to spin down the cells. Subsequent activation was done in CO2 Incubator for 6 hours 
away from light. Samples without stimulation or with Treg alone were used as controls. 2 
repetitions were performed for every condition. 
  After activation, the cells were washed and stained with 0.5µl Live/Dead Aqua, 8µl CD3 
PerCP-Cy5.5/ CD4 FITC/ CD25 PE, 2µl CD69 PE Cy7, 1µl CD8 APC_Cy7 and 1µl 
CD45RA ECD to a final 50µl volume (20minutes in the fridge, dark). Then the cells were 
washed and analyzed on LSR II. The gating strategy is showed in Figure 5. Suppression of 
CD69 or CD154 expression was calculated as (A-B) / A, where A is the mean frequency of 
positive cells in the sample with responder cells alone and B is the mean frequency of positive 
cells in the sample cultured with different Treg subset. 
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Figure 5: Gating strategy for the suppression assay. Gating strategy is shown from one representative donor 
with responder cells cultured alone. Treg are excluded from the analysis by gating on CD25lo cells; responder 
cells co-cultured with TregCM are used to set this gating as shown in the smaller dot plot. 
3.2.5.2 Suppression assay of proliferation and apoptosis 
Autologous PBMC were used as responder cells and labeled with 2 µM CFDA-SE for 3 
minutes, staining was stopped completely by adding 2ml ice-cold FCS for 1 minute. Cells 
were washed with RMPI medium twice afterwards. The CFSE labeled PBMC were cultured 
either alone or with Treg at a ratio of 1:1. However, the total number of all cells in each well 
was 100, 000 and final volume was 200µl with X-vivo medium. 105 Treg suppression 
inspectors were also added to each well for stimulation. Autologous Tconv were cultured with 
responder cells as well for controls. 2-3 repetitions were performed for every condition. After 
3-4 days, the culture is stopped according to the proliferation of the responder cells. 
  Supernatant of each well was collected and freezed for cytokines detection. Cells were 
washed with FACS buffer twice, then by Annixin V binding buffer once, discard supernatant 
and re-suspend cells in Annixin V binding buffer. Stain them with 2µl CD3 PerCP, 1µl CD4 
Alexa 700, 1µl CD8 APC_Cy7, 1µl Annexin V APC in a final 50µl for 20 minutes at room 
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temperature. Add 200µl Annixin V binding buffer to each well to stop the staining, 2µl DAPI 
was added before analyzing samples on LSR II. 
  Treg were excluded from the analysis by gating on CFSE+ cells. DAPI+Annexin V+ cells 
were regarded as dead cells with DAPI-Annexin V+ cells as apoptotic cells. Non-apoptotic 
cells with DAPI-Annexin V- populaiton was further analyzed for proliferation by CFDA-SE 
dilution as shown in Figure 6. 
 
Figure 6: Flow cytometric gating for proliferation and apoptosis assay was showed from a representative 
donor. (A) Unlabeled cells were used as the control to discriminate Treg from CFDA-SE labeled responder cells. 
(B) CFDA-SE labeled responder cells were analyzed with DAPI and Annexin V expression. DAPI+Annexin V+ 
cells were regarded as dead cells and DAPI-Annexin V+ cells were apoptotic cells. Non-apoptotic cells with 
DAPI-Annexin V- populaiton was further analyzed for proliferation by CFDA-SE dilution. (C) Responder cells 
were divided into non-T cells by CD3 expression and CD4 and CD8 T cells. All 3 sub-populations undergo same 
analysis as total PBMC for apoptosis and proliferation. 
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  The percentage of inhibition of proliferation was calculated as (A-B)/A ×100, where A was 
mean percentage of proliferating cells in responders alone and B was mean percentage of 
proliferating cells in responders with Treg or Tconv. 
  Calculation of percentage of apoptosis was done as B’/A’ ×100, where A’ was mean 
percentage of apoptotic cells in responders alone and B’ was mean percentage of apoptotic 
cells in responders with Treg or Tconv; i.e. >100 means apoptosis induction. 
3.2.6 Treg isolation and expansion 
3.2.6.1 Treg isolation 
Treg were isolated mainly with the isolation kits from Miltenyi according to the manual by 
MACS. Taking CD4+CD127dim/- regulatory T cell isolation kit as an example, the procedure is 
as following: non-CD4 cells and CD127hi cells were deleted by a negative selection with a 
cocktail antibody of these cells. If starting with 107 cells, cells were mixed with 10µl biotin-
antibody-cocktail and incubated for 10 min in fridge, then 30µl MACS buffer and 20µl anti-
biotin-microbeads were added and incubated for another 15 minutes in fridge. Cells were 
washed and re-suspended in 500µl buffer, which were transferred to a pre-rinsed LD column 
and washed twice with 1ml MACS buffer. Negative fraction was then labeled with 10µl CD25 
microbeads in a final 100µl volume. After incubation for 15 minutes in fridge and washing, 
cells were transferred onto MS column and washed 3 times with 500µl buffer; positive 
fraction was flushed out into second pre-rinsed MS column with 1 ml buffer out of the 
magnet.  The second column was put back to magnet again and washed 3 times with 500µl 
buffer. Final eluate from the second MS column was final fraction containing Treg. At last, 
centrifuge the eluate and re-suspend cells in X-vivo medium. 
3.2.6.2 Treg expansion in plate 
Treg expansion was mainly done according to the manufacture of human Treg expansion kit 
(Miltenyi). Briefly, 105 cells were place into one well of 96-well plate with 100 µl X-vivo 
medium plus 10% human AB serum, 500 IU Proleukin and 100nm Rapamycin. Cells were 
stimulated with CD3/28 beads with a ratio of 4 beads to 1 cell. Fresh medium were added 
every 2-3 days and cells were transferred into 24-well plate at day 14. After 3-wk expansion, 
beads were removed and cells were resting for 4 days. 
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  Regarding removing the beads, re-suspend cells in buffer at a density of up to 2×107 cells 
per 1 mL and vortex thoroughly; place the tube (1.5ml or 5ml) in the magnetic field of the 
MACSiMAG Separator for 3-5 min. Retaining the tube in the magnet, carefully remove the 
supernatant containing the MACSiBead-depleted cells and place in a new tube. If necessary, 
wash the cells and repeat it once. 
3.2.6.3 Treg expansion in G-rex10 device 
5×105 or 106 Treg were placed in 20 ml expansion medium in a G-Rex10 device and 
stimulated with CD3/28 beads with a ratio of 4 beads to 1 cell. 300IU additional proleukin 
was added every 10 days. After a 3-wk expansion, beads were removed and cells were resting 
for 4 days. 
3.2.7 DNA extraction and next-generation sequencing for TCR repertoire 
Total genomic DNA of TregN, CM, EM and Tconv from 6 healthy donors and TregN, M, 
TconvN, M from additional 4 healthy donors were extracted using QIAamp DNA Blood Mini 
Kit (QIAGEN). The CDR3 in the TCR-β chain of all these DNA sampls was amplified and 
sequenced on the ImmunoSEQ platform at Adaptive Biotechnologies using next generation 
sequencing technology (105, 119). 
3.2.8 Computation analysis 
The calculation of Shannon entropy (SE) in this study is mainly the same as we described 
before (30). The SE was normalized, i.e. divided by the natural logarithm (Ln) of the total 
number of distinct sequences in each sample. Thus, the normalized SE ranges from 0 and 1, 
where “0” indicates a population dominated by only one clone and “1” indicates the highest 
diversity, e.g. a cell population with many clones with similar frequencies.  
  The Moristita-Horn similarity (MH) index is a method to quantify the similarity of two 
populations such as TCR repertoires (31), it was applied in this research and calculated as 
described before (32).  
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3.2.9 Statistical analysis 
Statistical tests were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, 
USA). Significance between two groups was determined by paired-t-test if normal 
distribution is confirmed or Wilcoxon matched pairs test if not. 1-way ANOVA or repeated 
measures ANOVA analysis with Tukey correction were applied for comparison with more 
than 3 groups, correlation was determined by Spearman test. Details are noted in each figure 
legend. Significant difference was defined by the value of probability (p): *P<0.05; **P<0.01; 
***P<0.001.
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4. RESULTS 
4.1 Phenotypic analysis of Treg from healthy donors and Tx patients 
To the first aim, 3 FACS panels were established to evaluate the phenotype and activation 
pattern of Treg. Peripheral blood samples from 60 healthy donors (21 men; 39 women) and 22 
renal transplant recipients were collected for this study. 
4.1.1 The majority of Treg express central-memory phenotype increasing with age  
4.1.1.1 Treg frequency and subsets distribution regarding age and gender    
First, we addressed the question whether age or gender has an impact on the distribution of 
Treg subsets, which might influence the quality of a putative adoptive Treg therapy product. 
The total Treg (CD4+CD25hiFoxP3+CD127lo T cells) frequency in CD4 T cells and the Treg 
subset composition from 60 healthy donors were analyzed. The gating strategy is shown in 
Figure 7A. No significant impact of age on the frequency of total Treg in CD4 T cells was 
found in adults (Figure 7B). There was also no significant difference of the Treg proportion 
between male and female (Figure 7C). Regarding the heterogeneous composition of Treg in 
Figure 7A, we performed further analysis on Treg subsets in different age decades. As 
expected, the proportion of naïve cells (CD45RA+CD62L+) within the total Treg decreases 
with increasing age, reaching a plateau at the age period of 40-49 (Figure 7D). Further 
analysis of TregM subsets reveals that the majority (66.97% on average) of total Treg belongs 
to the central-memory (CM, CD45RA-CD62L+) phenotype with a clear impact of age (Figure 
7 E), but after the age of 40, the proportion becomes very stable. By contrast, the minority of 
Treg (12.28% on average) show the effector-memory (EM, CD45RA-CD62L-) phenotype 
without significant influence by age in adults (Figure 7F). In addition, Treg of healthy donors 
contained no terminally differentiated cells (TEMRA) (CD45RA
+CD62L-) at all (Figure 7G). 
Expression of other important Treg markers are also shown in Figure 7G, e.g.,  70.25% of 
total Treg are CD49d- , 93.60% are CTLA4+  and 78.80% are Helios+ . 
  Compared to Tconv, it is noted that Treg contain significantly less naïve and EM, but more 
CM pooulation than the respective Tconv (Figure 7H-J). Thus, the majority of Treg exhibit the 
CM phenotype, circulating mainly between blood and lymphoid organs. 
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Figure 7: Majority of regulatory T cells express central-memory phenotype increasing with age. (A) Flow 
cytometric gating scheme for total Treg and subsets: Starting from lymphocytes by FSC and SSC gating, 
doublets were excluded by FSC-H versus FSC-A gating and dead cells were excluded by live/dead aqua. Cells 
were further gated on CD3+CD4+, then CD25hiFoxP3+. CD127 was used to define Treg population as 
CD4+CD25hiFoxP3+CD127lo T cells, gating of this marker was based on total lymphocytes as showed in the 
small dot plot. Treg and Tconv were further analyzed into subsets. (B, C) There is no significant impact of age 
and sex on frequency of total Treg in CD4 T cells. (D) Proportion of TregN in total Treg population decreases 
with age. (E) Majority of Treg express CM phenotype with age. (F) Minority of Treg are EM cells without 
significant impact from age. (G) Summary of Treg subsets from all donors. (H-J) Treg contain less naive and EM 
but more CM subsets compared to respective Tconv. Data are from 60 healthy donors from the age of 19 to 87 
(21 men; 39 women), distribution of TregCM and TregEM by age is from 36 of total. One-way AVOVA with 
Tukey correction was used for Figure (B, D, E, F, G); unpaired-t-test was applied for Figure B; Wilcoxon 
matched pairs test was used for Figure (H-J). (Lei et al. in Preparation) 
4.1.1.2 Each Treg subset is weakly positively correlated with Tconv subset regarding the 
proportion 
Compared with the respective Tconv subsets, it was found that the proportion of naïve Treg 
was positively correlated with that of naive Tconv (Spearman r=0.5627) (Figure 8). CM and 
EM Treg were also weakly correlated with their respective Tconv counterparts. These results 
suggest some relation of memory generation between both CD4 populations, Treg and Tconv, 
as period of antigens exposition or homeostatic expansion over age. 
 
Figure 8: Frequency of NAÏVE, CM and EM cells in Treg were positively correlated with their frequency 
in donor-matched respective Tconv subsets. (A) Frequency of naïve cells in total Tconv and Treg were showed 
as values in X-axis and Y-axis separately. (B, C) Frequency of central memory (CM) and effector memory (EM) 
cells in Tconv and Treg were also compared. Correlation of same cell type in Treg and Tconv was analyzed with 
Spearman test. 
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4.1.2 Treg up-regulated only CD137 while Tconv up-regulated both CD137 and CD154 
upon TCR stimulation 
CD137, also called 4-1BB, is a member of the TNFR super family with co-stimulatory 
function; 4-1BB stimulation plays an important role in cell survival, proliferation and function 
in CD4 and CD8 T cells (120). CD154, also named CD40L, is another important activation 
marker for conventional T cells and its expression can be used to define antigen-reactive 
T cells (121). T cells activated by CD2/3/28 beads could up-regulate the expression of these 
two activation markers. Therefore, the expression of CD137 and CD154 were applied to 
assess the activation status of T cells in the study. 
4.1.2.1 Total Treg up-regulated only CD137 expression 
Very recently, Schoenbrunn et al. demonstrated a different expression pattern of Treg versus 
Tconv. Tconv up-regulate CD154 and partly also CD137, while Treg selectively up-regulate 
CD137 only (122). We have confirmed these data in all our healthy donors. Different 
activation patterns in Treg and Tconv was showed in Figure 9. Total PBMC were poly-
clonally stimulated. Treg and Tconv were further analyzed for expression of CD137 and 
CD154: i) around 60% of Treg up-regulated CD137 expression with absence of CD154 
(Figure 9B, C), which was regarded as pure activated antigen-reactive Treg; ii) almost no 
CD154+CD137- cells were found in Treg population; iii) <5% of Treg up-regulating both 
CD137 and CD154 were regarded as “contaminated” cells (Figure 9B, E) because of low 
expression of Helios and low demethylation status of FoxP3 region. These “contaminated” 
cells might be induced Treg, as they express the phenotype (109). Activated Tconv, expressed 
CD154+ cells (10% of CD154+CD137- and 40% of CD154+CD137+ in Figure 9D, E) and 20% 
of CD137+CD154- cells (Figure 9C). In summary, Treg, as gated by our strategy (mostly 
nTreg), do not up-regulate CD154 but CD137 following TCR activation. 
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Figure 9: Treg up-regulated only CD137 while Tconv up-regulated both CD137 and CD154 upon TCR 
stimulation. (A) Schema of activation assay, red cells represent Tconv, green cells with Foxp3 inside represent 
Treg and orange cells mean all other cell types in PBMC. (B) CD137 and CD154 expression from one 
representative donor was showed; un-stimulated cells were used as the control. (C) Significant higher proportion 
of CD137+ cells was found in Treg than Tconv. (D) Tconv expressed CD154 while Treg did not. (E) Large 
amount of Tconv were also CD137+CD154+ cells. (n=30, Wilcoxon matched pairs test.)  
4.1.2.2 Memory Treg contained higher CD137+ cells, but less CD137+CD154+ cells than 
naive Treg upon TCR stimulation 
Due to the functional comparison of Treg subsets that would be performed later, here 
activation patterns in naïve Treg (Treg N), memory Treg (Treg M) and Tconv subsets 
(Naive/Memory) were compared in Figure 10. Naïve and memory cells were discriminated by 
further CD45RA expression. We found slightly but significantly higher expression of 
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CD137+CD154- cells, suggesting higher activation level in memory Treg. Interestingly, the 
proportion of double positive cells (CD137+CD154+) was even slightly lower in memory than 
naïve Treg (Figure 10A, B).  
 
Figure 10: Distinct activation patterns in Treg and Tconv subsets. Treg and Tconv population were further 
separated into naïve (CD45RA+) and memory (CD45RA-) cells and expression of CD137 and CD154 on 
the subpopulations were compared. (A, B) Treg M contained slightly higher expression of CD137 while Treg 
N contained more double positive cells. (C-E) Expression of CD137 and CD154 as single positive and double 
positive cells on Tconv N/M were compared: Tconv M showed slightly higher fraction of CD137+CD154+ cells 
than Tconv N did. (F, G) Tconv M contained more CD137+ cells than Tconv N while no difference was found 
between them regarding CD154 expression. (n=30, Wilcoxon matched pairs test.) (Lei et al. in Preparation) 
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  Regarding Tconv, majority of activated Tconv were CD137+CD154+ and significantly higher 
fraction of double positive cells were found in memory Tconv (mean 37.19%) than naïve 
Tconv (mean 33.70%) (Figure 10D). As for total CD137+ cells (% CD137+CD154- plus % 
CD137+CD154+) in both populations, the result was almost the same (Figure 10F). However, 
lower proportion of CD154+CD137- cells were found in memory Tconv than naïve ones 
(Figure 10E). When only CD154+ cells (CD154+CD137- plus CD154+CD137+) were taken 
into account, no significant difference was found between Tconv N and Tconv M (Figure 
10G). 
4.1.2.3 FoxP3+Helios+ cells may define more pure Treg population regarding CD154 
expression 
 
Figure 11: Helios expression is restricted to Treg fraction defined by no CD154 expression.  (A-C) Dot plots 
of CD4 T cells from one representative donor were showed, gray area represents unstimulated sample. (D) 
FoxP3+Helios- cells are able to express CD154 while FoxP3+Helios+ are not. (n=30, Wilcoxon matched pairs 
test.) 
  Helios is an Ikaros transcription factor family member and could up-regulates FoxP3 by 
binding to the foxp3 promoter (123). Here, when we used CD154 as an exclusion marker for 
Results 
35 
 
Treg, almost no CD154+ cells were found in FoxP3+Helios+ cells while around 15% of cells 
expressing CD154 were found in FoxP3+Helios- population (Figure 11). 
4.1.3 Treg in Tx patients contained more effector-memory cells and were more 
susceptible to activation-induced cell death 
4.1.3.1 Tx patients contained more TregEM than healthy donors with similar age  
 
Figure 12: Tx patients contained more effector-memory and TEMRA cells than healthy donors in Treg 
population with same age period. (A) Increased Treg frequency was found in stable patients above 4 years post  
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renal transplantation than it in healthy donors (HC). (B) Decreased proportion of naïve cells in total Treg in Tx 
patients than HC donors with same age period (> 40 years). (C) Similar frequency of central memory cells was 
found in these Tx patients and HC donors. (D) Tx patients contained increased number of effector memory cells 
than HC donors. (E) Higher frequency of TEMRA (CD45RA
+CD62L-) cells was found in some Tx patients. All 
HC donors and Tx patients compared here are above 40 years old. (N_HC donors=21， N_TX patients=20, 
Mann Whitney test.) (Lei et al. in Preparation) 
  Due to the important role of Treg in immune tolerance, Treg frequency and phenotype in Tx 
patients was also compared with that in healthy donors. In Tx patients post renal 
transplantation more than 4 years, increased proportion of Treg has been observed. As the 
proportion of both naïve and memory cells in Treg were quite stable in healthy donors older 
than 40 years (Figure 7D, E, F), only probands above 40 years old were selected from both 
groups to make it comparable. Significantly less naïve Treg was found in Tx patients 
compared to healthy ones (Figure 12B); on the other hand, more TregEM were observed in Tx 
patients (Figure 12D) although there was no significant difference regarding TregCM 
proportion (Figure 12C). Interestingly, Small proportion (1.1%) of TEMRA (CD45RA
+CD62L-) 
cells were found from Tx patients while not at all was observed from healthy donors (Figure 
12E). 
4.1.3.2 Treg in Tx patients were pre-activated in periphery while Tconv were not 
without in vitro stimulation 
Activation pattern of Treg and Tconv from Tx patients were analyzed the same way as we did 
for healthy donors. Interestingly, some pre-activation pattern was observed in Treg (Figure 
13A) from Tx patients, rather than in Tconv (Figure 13B) without any TCR stimulation. In 
un-stimulated samples from Tx patients, >20% of CD137+CD154- Treg were observed while 
almost no positive Treg were found in healthy donors, indicating some pre-activation in Tx 
patients, e.g. by allo-antigens exposure. However, we didn’t see this pre-activation in Tconv 
from the same patients (Figure 13C). Regarding the specific Tconv marker (CD154) 
expression, we did see up-regulation of CD154 expression in Tconv upon in vitro stimulation 
(Figure 13D). CD137 expression in Tconv was also up-regulated in Tconv after stimulation 
(Figure 13C), suggesting that our in vitro stimulation and FACS staining themselves worked 
well. This early activation in Treg rather than Tconv may relate to the active suppression to 
allo-reactivity of Treg in these patients more than 4 years post renal transplantation. 
Results 
37 
 
 
Figure 13: Peripheral Treg in Tx patients rather than healthy donors were pre-activated. (A) CD137 and 
CD154 expression in Treg and Tconv in one representative unstimulated Tx patient. (B) CD137 and CD154 
expression in same stimulated patient. (C) Tx patients have significantly higher CD137+CD154- cells in Treg 
population than healthy donors without in-vitro stimulation. (D) Tonv cells in Tx patients up-regulate CD154 
expression upon in-vitro stimulation. (N_Healthy=30， N_Tx patients=22, Mann Whitney test was used for 
“HC_UN Treg” and “Tx_UN Treg”; Wilcoxon matched pairs test was for “Tx_UN Treg” versus “Tx_UN 
Tconv” and “Tx_UN Tconv”  versus “TX_ST Tconv”. “UN” means un-stimulated and “ST” means stimulated.  
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4.1.3.3 Peripheral Treg in Tx patients are more susceptible to activation-induced cell 
death  
Besides the pre-activation of Treg in Tx patients, total Treg proportion in CD4 T cells was 
compared before and after in vitro stimulation. Surprisingly, a dramatic decrease of Treg 
proportion was found in Tx patients after TCR stimulation (Figure 14A). However, this 
phenomenon was not observed before and after same stimulation in healthy donors (Figure 
14B). Together with pre-activation and more effector-memory cells in Treg from Tx patients, 
these data suggest that Treg in Tx patients are more pre-activated in vivo, representing a 
sensitive balance of activation and regulation. 
 
Figure 14: Peripheral Treg in Tx patients are more susceptible to activation-induced cell death. (A) Treg 
frequency in Tx patients dropped dramatically after in-vitro poly clonal stimulation. (B) Treg frequency in 
healthy donors did not change significantly before and after same stimulation. (N_HC=30, N_Tx=22, Wilcoxon 
matched pairs test) 
  Taken together, we have studied Treg frequency and heterogeneity in both healthy donors 
and Tx patients. Similar subsets composition of naïve, CM and EM cells as Tconv was found 
in Treg population, but Treg contained more CM cells than respective Tconv in healthy 
donors. Based on different age decades, stable frequency of total Treg in CD4+ T cells was 
found without significant gender and age differences in healthy donors. Proportion of TregN 
decreased while TregCM increased with age, however, above 40 years old, the frequency 
change upon age decades was not significant any more.  
  Treg and Tconv have different activation patterns upon poly-clonal stimulation: Treg showed 
mainly CD137+CD154- pattern while Tconv showed mainly CD154+CD137- or 
CD154+CD137+ pattern. However, both memory Treg and memory Tconv have more CD137 
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expression than their naïve counterpart, which may be important for Treg and Tconv memory 
functionality and survival. 
  In Tx patients expressing > 4 years stable renal graft function, increased Treg frequency 
indicated dominate regulation to some extent. May be due to the allo-antigens experience, less 
naïve cells and more EM cells were observed compared with healthy donors with same age 
period. Interestingly, a pre-activation status in Treg was also observed only from Tx patients 
rather than healthy donors, which may be related to active suppression to allo-reactivity of 
Treg in these Tx patients with stable renal graft function. Furthermore, dramatic decreased 
Treg frequency upon TCR stimulation may indicate high susceptibility of these cells in Tx 
patients to activation-induced cell death. 
4.2 Functional analysis of Treg subsets: central memory Treg show enhanced 
suppression efficiency than naïve Treg  
The counterpart of Treg, Tconv were also composed of N, CM and EM subsets (124), whose 
contributions to recall response have been intensively discussed for decades. In CD4 Tconv, 
TCM proliferate extensively whereas TEM show less proliferation in response to recall antigens 
and have shorter telomeres (125). In CD8 T cells, human TEM cells also display immediate 
cytotoxic activity at early memory phase of infection while TCM populations acquire effector 
function after short-term stimulation and make a markedly greater contribution to recall 
responses from later memory time points because of their increased proliferative potential 
(124, 126-131). However, the contribution of the subsets in Treg is still rarely known up to 
now. Therefore, further studies on the suppressive functionality of the three Treg subsets were 
conducted in this part. 
4.2.1 Freshly isolated TregCM showed enhanced suppression activity to early 
activation of both CD4 Tconv and CD8 Tconv 
4.2.1.1 TregCM contained higher FoxP3 demethylation level than TregN 
Treg subsets as Naive, CM and EM were sorted by MACS and FACS as described in the 
method 3.2.3. Gating for FACS sorting was showed in Figure 15. CD25hiCD45RA+ cells were 
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sorted as naïve Treg; CD25hiCD45RA- cells in P5 were further gated into CD62L+ cells as 
TregCM; CD62L- cells as TregEM. 
 
Figure 15: FACS sorting strategy was showed for Treg N, CM and EM subpopulations. 
  TregN, CM and EM were sorted, the purity of which were controlled by phenotype 
evaluation with FACS staining and demethylation of FoxP3 locus (TSDR). The TSDR 
experiment was performed by Katrin Vogt (Institute of Medical Immunology, Charité 
University Medicine Berlin). 
  The main phenotype evaluation of the freshly sorted Treg subsets was shown in Figure 16A, 
B by expressing both FoxP3 and Helios, an Ikaros transcription factor family member that 
might up-regulate FoxP3 by binding to the FoxP3 promoter (33). From the FoxP3 
demethylation of TSDR in Treg subsets (Figure 16C), TregCM revealed a higher FoxP3 
demethylation of TSDR than TregN, reaching almost 100% (Figure 16C). 
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Figure 16: Central-memory Treg contained higher FoxP3 demethylation level of TSDR than naïve Treg. 
(A) Flow cytometric gating for sorted Treg from a representative donor. (B) > 80% of all TregN, TregCM and 
TregEM express FoxP3 and Helios. Gray area represents isotype control. (C) Higher FoxP3 demethylation status 
was observed in TregCM than TregN subset. Results are form 6 donors and data of Treg EM are from 4 of them. 
Statistics between TregN and TregCM was done with paired t test. 
4.2.1.2 TregCM showed enhanced suppression activity to early activation of both CD4 
Tconv and CD8 Tconv 
Suppression activity of Treg subsets was performed by using suppression of activation 
markers (CD69, CD154) expression on stimulated Tconv, which could predict the suppressive 
ability for cells proliferation and cytokines production at 4 days (118). Gating strategy of the 
whole analysis was described in chapter 3.2.5.1 of the methods part (Figure 5). One 
representative example of CD69 and CD154 expression on responder cells with or without 
Treg subset is shown in Figure 17A. Suppression of CD69 expression on CD4 T cells 
(expression range: 72.2%-89.2%) by TregN, TregCM and TregEM is shown in Figure 17B. 
Suppression of CD154 expression on CD4 T cells (expression range: 52.10%-78.70%) is 
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shown in Figure 17C. Interestingly, in this early activation stage, TregCM showed enhanced 
suppression of CD69 and CD154 expression compared to TregN on CD4 T cells, similar 
suppression tendency was also observed on CD8 T cells (CD69 expression range in CD8+ 
T cells: 46.6%-77.6%) (Figure 17D), but no significant difference was found between 
TregCM and TregEM in all cases. We did not analyze suppression of CD154 on CD8 T cells 
because the expression was very low even without Treg (< 2%). 
 
Figure 17: TregCM showed enhanced suppression of early activation in CD4 and CD8 Tconv than TregN. 
(A) Representative examples of CD69 and CD154 expression on CD4 T cells with or without Treg subset, gray 
area indicated un-stimulated cells. (B, C) Suppression of CD69 and CD154 expression on CD4 T cells by 
different Treg subsets. (D) Suppression of CD69 expression on CD8 T cells. Data were from 9 donors with 2-3 
repetitions for every subset in each donor. Mean values of repetitions were showed and analyzed for statistics 
(Repeated measures ANOVA with Tukey correction). (Lei et al. in Preparation) 
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4.2.1.3 Suppression of Tconv by TregCM was dose-dependent and mainly focused on 
T cells, rather than CD3- cells 
 
Figure 18: Suppression of early activation by TregCM was dose-dependent and mainly seen on T cells. (A-
B) Stronger suppression of CD69 and CD154 expression in CD4 Tconv by high dose (HD) TregCM was 
observed compared to low dose (LD) Treg. (C) Dose dependent suppression of CD69 by TregCM was also found 
in CD8 Tconv. (D) Suppression by TregN was stronger in CD4 Tconv compared to respective CD8 Tconv, but 
not in CD3- cells. (E, F) Same suppression tendency to T cells was also observed by TregCM and EM. (n=8, 
Paired t test). (Lei et al. in Preparation) 
Dose dependency by Treg subsets to the suppression of early activation in Tconv was 
observed (Figure 18A-C). Interestingly, slightly higher suppression of early activation was 
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found in CD4 T cells than in CD8 T cells by all 3 Treg subsets (Figure 18D, E, F). However, 
no suppression was observed regarding CD69 expression on non-T cells. 
  Due to similar subsets composition of Treg and Tconv, Tconv are also divided into naïve and 
memory subpopulation by gating in the analysis. However, all Treg subsets (N, CM, EM) 
showed comparable suppression to the activation of both naïve and memory Tconv via TCR 
stimulation (Figure 19). 
 
Figure 19: Treg subsets showed comparable suppression to activation of naïve and memory Tconv. (A-C) 
Suppression of CD69 expression on naïve and memory CD4 Tconv by Treg N, CM, EM were shown separately. 
(D-F) Comparable suppression of CD154 expression was observed on CD4 Tconv subsets. (G-I) Comparable 
suppression of CD69 expression was also observed on CD8 Tconv subsets (Wilcoxon matched pairs test). 
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4.2.2 Treg subsets showed similar suppression activity to both T cells and non-T cells 
regarding proliferation of non-apoptotic responder cells 
 
Figure 20: No Significant difference was found among Treg subsets regarding inhibition of the 
proliferation of non-apoptotic responder cells. (A) Proliferation of responder cells was showed in responder 
cells alone, or co-cultured with Treg subsets respectively from one representative donor. (B-D) No significant 
difference was found between any pair of Treg subsets regarding proliferation of CD4 T cells or CD8 T cells. (E) 
Treg subsets also inhibit proliferation of CD3- cells and TregCM showed stronger suppression than TregEM. 
Data were from 6 donors and Treg EM was from 5 of them with 2-3 repetitions for each donor (Paired -t-test). 
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  Proliferation and apoptosis of responder cells co-cultured with Treg were examined as 
described in chapter 3.2.5.2 of the methods part. Regarding inhibition of the proliferation of 
non-apoptotic cells, no significant difference was found among TregN, CM, EM (Figure 20A, 
B). Similar phenomenon was observed in CD4 and CD8 T cells population (Figure 20C, D) as 
well. In addition, suppression of proliferation was also found here in non-T cells population, 
which should be mainly B cells and NK cells as lymphocytes were gated first (Figure 20E). 
4.2.3 Treg CM induced apoptosis to CD3- cells while TregN did not. 
 
Figure 21: Apoptosis of total PBMC induced by Treg CM was mainly seen on CD3- cells. (A) TregCM could 
induce apoptosis to total PBMC while TregN or Treg EM could not. (B, C) No apoptosis induction was found on 
either CD4 T cells or CD8 T cells by any Treg subset. (D) Only TregCM induced apoptosis in CD3- cells. 
“Control” was responder cells alone. (n=6, Treg EM are from 5 of the total 6 donors. Wilcoxon signed rank test 
was for comparison of any subset and “control”; paired-t-test was for comparison of TregN and TregCM.)  
  The apoptosis induction of responder cells by different Treg subsets was studied. First of all, 
apoptosis in total PBMC was caused only by TregCM rather than TregN (Figure 21A). When 
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total lymphocytes were divided into CD4 T cells, CD8 T cells and non-T cells (CD3-) by 
gating, no significant apoptosis induction was found by any Treg subset in CD4 and CD8 T 
cells (Figure 21B, C), only apoptosis of CD3- cells was observed by TregCM rather than 
TregN (Figure 21D), indicating that apoptosis of total PBMC induced by TregCM was mainly 
focused on CD3- cells. 
  Furthermore, when apoptotic cells during proliferating process and un-proliferating process 
were separated, the apoptosis induction by TregCM was mainly observed in un-proliferating 
process (Figure 22).  
 
Figure 22: Apoptosis induced by Treg CM mainly occurred in non-proliferating cells. (A) DAPI- responder 
cells were further analyzed for Annexin V expression versus proliferation. Apoptosis in proliferating cells were 
showed in P1 and in un-proliferating cells were showed in P2. Regarding apoptosis induction in proliferating 
cells, mean % of P1 in responders alone was regarded as A’; mean % of P1 in responders with Treg was B’; 
B’/A’ ×100 generated final “% apoptosis” in proliferating cells as Y-axis indicated in Figure B. Same calculation 
in P2 was performed to show “% apoptosis” in un-proliferating cells in Figure C (n=6, Treg EM are from 5 of 
the total 6 donors). (Lei et al. in Preparation) 
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4.2.4 Enhanced suppression activity of TregCM may be related to particular cell-cell 
interaction due to higher CTLA-4 expression on TregM than TregN 
Based on the results from the enhanced suppression of early activation and apoptosis 
induction by TregCM than TregN, the mechanism behind was also explored partly. CTLA-4 
expression on memory Treg and naïve Treg were compared because of its highly important 
role in cell-cell contact suppression mechanism. As what we expected, memory Treg did 
express higher level of CTLA-4 than naïve Treg (Figure 23).  
 
Figure 23: Memory Treg express higher CTLA-4 than naïve Treg. (A) Treg in peripheral blood were 
separated into naïve and memory sub-populations by CD45RA expression, shown from one representative donor. 
(B) CTLA-4 expression was compared in naïve and memory Treg. Gray area represents expression in Tconv. (C) 
Significantly higher geometric mean fluorescence intensity (MFI) of CTLA-4 was observed in memory Treg. 
(n=12, paired-t-test).  
  In summary, TregCM showed a stronger expression of FoxP3 and their demethylation level 
of the FoxP3 TSDR was even higher than the one of TregN. Most importantly, they expressed 
significantly stronger suppressive capacity to prevent early activation of Tconv compared to 
TregN and similar ability to inhibit proliferation of Tconv. Moreover, TregCM rather than 
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TregN were able to induce apoptosis of responder cells; the apoptosis was mainly seen on 
CD3- cells (mainly B cells and NK cells). Lastly, the enhanced regulation of memory Treg 
may be related to CTLA-4 dependent cell-cell contact mechanism. Thus, Treg could not only 
suppress activation of T cells, but also inhibit proliferation of both T cells and non-T cells and 
induce apoptosis in non-T cells, in parallel. Treg CM showed significantly stronger capacity 
than TregN in these processes. 
4.3 Expansion of Treg and subsets indicated promising clinical translation for Treg 
therapy 
4.3.1 Expansion with rapamycin could keep FoxP3 expression and suppression 
function of Treg 
Due to the low frequency of Treg in peripheral blood, expansion of them in vitro without 
losing their suppression activity is a big issue for clinical translation of adoptive Treg therapy. 
Rapamycin, a mTOR inhibitor, plays a key role in achieving this. After 3-wk expansion with 
rapamycin, the expansion rate of Treg was less effective (Figure 24A). However, expanded 
Treg with rapamycin did keep most of FoxP3 and Helios expression while cells without 
rapamycin lost them dramatically (Figure 24B). In contrast to Tconv, almost no IL2, IL17 and 
IFNg production were found in expanded Treg with rapamycin after PMA/Ionomycin 
stimulation, although small amount of TNFα was detected. By contrast, in expanded Treg 
without rapamycin, >20% IL2 and IFNg producing cells and >50% TNFα producing cells 
were observed (Figure 24C). 
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Figure 24: Expansion of Treg with rapamycin could keep Foxp3 expression and inhibit effecter cytokine 
production. (A) Expansion of Treg with rapamycin led to slightly lower expansion. (B) Expansion of Treg with 
rapamycin could keep Foxp3 expression. (C) Expansion with rapamycin could minimize regeneration of effector 
cytokine producing cells. (n=6, paired-t-test). 
4.3.2 Enhanced expansion of Treg with G-Rex device, even closer to translation 
Culturing Treg with poly-clonal stimulation in conventional cell culture plates could achieve 
around 20 fold of expansion stably. But this is still not enough for clinical translation as from 
preclinical data a >50 fold expansion of Treg from 50-100 ml blood is required. G-Rex device 
is a gas-permeable and GMP-compliant cell culture device. Expansion of Treg in this G-
Rex10 device could enhance expansion to at least 50 fold (Figure 25A) and even higher with 
increased starting cell numbers. Regarding phenotype, Treg marker (FoxP3 and Helios) 
expression in expanded cells from plate, and G-Rex10 device were comparable, i.e. >70% of 
the cells expressed FoxP3 and half of them expressed Helios (Figure 25B, C).  
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Figure 25: Expansion of Treg in G-Rex10 device could significantly increase the expansion without losing 
FoxP3 expression. (A) Higher expansion of Treg in G-Rex10 device. (B, C) Both of the expansion could keep 
FoxP3 expression and half amount of Helios expression. Expansion data in plate were from 6 donors and in G-
Rex10 were from 4 of them (Paired-t-test). 
  Similar to the cells expanded in plates, small amounts of IFNg and TNFα but no IL2 and 
IL17 were detected in 3-wk expanded Treg in G-Rex 10 device upon in vitro PMA / 
Ionomycin stimulation (Figure 26). Therefore, expansion of Treg in the GMP-compliant G-
Rex device contributes significantly to Treg expansion, thus promotes the clinical translation 
of Treg therapy moving forward. 
Results 
52 
 
 
Figure 26: Prevention of effector cytokines production after expansion in G-Rex10 device was similar to 
expansion in plates. Cytokine production of expanded Treg in G-Rex10 from one representative donor was 
shown. Unstimulated cells (UN) were used as the control for gating on stimulated ones (ST).  
4.3.3 Shift from naïve to memory Treg phenotype after expansion is associated with 
enhanced suppressive capacity  
Freshly isolated TregCM show a more enhanced suppressive capacity than TregN regarding 
activation, proliferation and apoptosis induction of responder cells (Results 4.2). Functional 
analysis of Treg subsets were further performed after expansion with polyclonal stimulation in 
presence of rapamycin and IL-2 for 3 weeks. Firstly, no significant difference was found 
between TregN and TregCM regarding expansion, but proliferation of TregEM was very poor 
(Figure 27A), which was in agreement with a previous report (132). Therefore, we only 
focused on the comparison of TregN and TregCM. After 3-wk expansion, naïve Treg lost most 
of the CD45RA expression (Figure 27B) and diverted into CM phenotype (Figure 27C); Most 
TregCM were still in CM phase although few of them diverted into TregEM (Figure26C, D). 
These subsets could keep more than 70% of FoxP3 expression after expansion (Figure 27E). 
Zooming into these FoxP3+ cells in each cell type, naïve Treg kept all their Helios expression 
as compared with freshly sorted cells; however, TregCM lost >50% Helios expression (Figure 
27F). Interestingly, expanded TregN obtained enhanced suppressive activity to the level of 
isolated and expanded TregCM. 
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Figure 27: Naïve Treg converted into TregCM show enhanced suppression activity after expansion with 
rapamycin, while TregEM proliferate poorly. (A) Similar expansion of TregN and TregCM is observed after 
3-wk expansion with rapamycin and proleukin, but proliferation of TregEM is very poor. (B) TregN lost naïve 
phenotype dramatically after expansion. (C) >80% expanded TregN expressed CM phenotype while majority of 
TregCM still kept CM phenotype. (D) Small proportion of expanded TregN and TregCM converted into EM 
phenotype. (E) TregN and TregCM kept >70% FoxP3 expression after expansion. (F) Expanded TregCM lost > 
50% Helios expression while TregN did not. (G, H) Expanded TregN acquired enhanced suppression activity 
compared to freshly isolated ones. Data are form 5 donors while expansion of Treg EM is from 4 of them 
(paired-t-test). (Lei et al. in Preparation) 
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  In short, expansion of Treg with rapamycin could keep FoxP3 expression and their 
suppression activity; moreover, expansion in gas-permeable and GMP-compliant device G-
Rex 10 could enhance significantly expansion to at least 50 fold using poly clonal stimulation 
without losing FoxP3 expression. As for Treg subset, expanded naïve Treg converted mainly 
into TregCM keeping FoxP3 and Helios expression with enhanced suppression activity while 
expanded TregCM kept FoxP3 expression but lost some Helios expression, nevertheless, they 
still showed equivalent suppressive activity before and after expansion, but proliferation of 
TregEM was very poor. 
  Together with the previous data, we concluded that the majority of Treg in peripheral blood 
from healthy donors and Tx patients stayed in central-memory phase, showing most efficient 
suppression regarding early activation, proliferation and apoptosis induction of other immune 
cells (mainly T cells, B cells, NK cells). Consequently, TregN converted into TregCM and did 
more efficiently the regulation job. Cell-cell contact suppression was one of the mechanisms 
behind this enhanced suppression efficiency, due to higher expression of CTLA-4 on memory 
Treg than naïve ones. However, TregEM might be the terminal differentiation phase as they 
proliferated very poorly. This hypothesis was strengthened once more by subsets distribution 
in Tx patients that they were pre-activated expressing more EM phenotype and more 
susceptible to activation-induced cell death. 
Results 
55 
 
4.4 TCR repertoire analysis indicated memory Treg derived from naïve ones rather 
than Tconv 
Enormous T cell receptor (TCR) repertoire clonal diversity is essential for T cells to recognize 
millions of antigens to exert immune responses. Thus, apart from playing a significant role in 
monitoring infections and diseases, analysis of TCR repertoire is also an important method to 
study the relationship between different cell lineages or cell types in the process of 
differentiation.  
  Based on the third aim of this project, we would figure out whether Treg might be derived 
from naïve ones in an antigen-driven process or induced from Tconv, as shown for TGFβ 
(109). In order to clarify the differentiation relationship between Treg subsets and Tconv, 
Treg (N, CM, EM) and Tconv from 6 healthy donors and Treg (N, M) and Tconv (N, M) from 
additional 4 healthy donors were prepared for DNA extraction, subsequently applied to 
TCRβ-chain repertoire analysis in this study using next-generation sequencing (NGS) and 
bioinformatic tools. The bioinformatics computing of TCR repertoire data with Shannon 
entropy and the Morisita-Horn similarity (MH) index has been done by Leon Kuchenbecker 
and Prof. Avidan U. Neumann (Berlin-Brandenburg Center for Regenerative Therapies, 
Charité University Medicine Berlin) for collaboration. 
4.4.1 Next-Generation Sequencing (NGS) is a much powerful tool for TCR repertoire 
analysis 
Third complementarity-determining region (CDR3) is the most variable region of TCRβ-
chain, thus analysis of TCRβ-chain repertoire is always focused on CDR3, which contain 
sequences encoded by V, D, J gene segments. The conventional and classic way is to use 
TCRβ-chain spectratyping for measuring CDR3 length.  
  The distribution of CDR3 length in every V-Family of TCR β-chain from 3 representative 
donors is shown in Figure 28. Normal distribution in TregN indicates polyclonal composition 
of the repertoire; in contrast, abnormal distribution in TregCM especially TregEM suggest 
clonal expansion in those Vβ families, e.g. Vβ4 and Vβ9 in TregEM. However, CDR3 length 
distribution could not provide direct sequence information at clonal level. Consequently, a 
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new technology for TCR repertoire analysis is essentially required to visualize clonal 
relationship of cell subsets. 
 
Figure 28: CDR3 length distortion of Vβ families of Treg subsets indicates indirectly clonal expansion of 
memory Treg. CDR3 length distribution in all V-families of TregN, TregCM, TregEM from 3 donors were 
shown separately. Different color represents different donor. 
  Next generation sequencing (NGS) is the powerful new technology to analysis TCR 
repertoire at a sequence level with V-gene and J-gene composition. Treg subsets and Tconv 
from total 10 donors were analyzed for their TCR repertoire by this high-through put 
sequencing at Adaptive Biotechnologies (USA). The average obtained total reads from each 
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cell type were 660,000 with average unique sequences of 198,000. Sequence composition of 
naïve Treg from one representative donor was shown as a 3D image in Figure 29 showing all 
V and J-genes.  Poly clonal distribution was observed with highest frequency of a single clone 
as low as 1.1%. 
 
Figure 29: Poly clonal distribution of TCR repertoire from TregN was observed by using NGS with 
frequencies of single clones lower than 1.1%. 
4.4.2 Memory Treg seems to be derived from naïve Treg rather than Tconv suggesting 
an antigen-driven process 
4.4.2.1 Clonal expansion in memory Treg compared to naïve ones 
The frequencies of the top 1,000 clones (defined by unique V, J and CDR3 sequence) of each 
cell type from one representative donor is shown in Figure 30A according to the rank. Clones 
with much higher frequencies are observed in TregCM or EM compared to TregN, indicating 
clonal expansion in the memory Treg repertoire. Additionally, the Shannon entropy (SE) is 
one of the most common and robust tools for measuring diversity and complexity of a data 
set, thus widely used in analyzing immunoglobulin repertoire diversity (35). A reduced SE in 
memory Treg confirms clonal expansion with statistical significance (Figure 30B).    
  To determine the source of expanded memory Treg clones – from Tconv (induced Treg) or 
from TregN in an antigen-driven process, we analyzed all the obtained distinct sequences 
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from Treg subsets, e.g., all the unique sequences of TregN and TregCM from one 
representative donor are shown in Figure 30C with their frequencies in each subset. As an 
example, the clone highlighted in Figure 30C has a frequency of 0.12% in TregN while in 
TregCM it has a frequency of 4.17%, suggesting approximately 35-fold expansion of this 
specific clone in TregCM. The same clonal expansion was analyzed in all memory-naïve pairs 
from all 10 donors, as shown in Figure 30D. It reached up to 200-fold clonal expansion in the 
memory Treg subset (CM or EM) and up to 500-fold in total memory Treg repertoire 
compared to the TregN pool. 
 
Figure 30: Visible clonal expansion is observed in memory Treg compared to naïve ones by NGS. (A) 
Frequency of the top 1,000 clones of the TCR repertoires in each cell type is shown according to the rank from 
one representative donor. (B) Significantly decreased normalized Shannon Entropy (SE) in memory Treg than 
naïve ones indicate strongly clonal expansion in memory phase. (C) Clones in TregN and TregCM were plotted 
according to their frequency in TregN and TregCM. Green rhombus represents the clone detected only in TregN; 
blue triangle represents the clone detected only in TregCM and cross represents shared clone between TregN and 
CM. (D) Highest clonal expansion from naïve Treg repertoires are shown both in memory Treg subset (CM or 
EM) and total TregM population from 10 donors. (Lei et al. in Preparation) 
Results 
59 
 
4.4.2.2 Memory Treg seem to be derived from naïve ones rather than Tconv with highest 
similarity within CM/EM 
In addition to the shared clones with highest expansion rates from naïve to memory Treg 
repertoire, the total number of overlapping clones from all sequences in our groups were 
compared, including TregCM with EM, memory Treg subsets (CM or EM) with TregN, and 
memory Treg subsets with Tconv from same donors as shown in Figure 31A; the percentage 
of overlapping clones was calculated as fraction of clones in the total number of clones in the 
latter cell population for each pair (Figure 31A). Interestingly, there is an overlap of more than 
25% between TregCM and TregEM. Although the TCR repertoire of TregN is very diverse 
and the individual clones therefore very rare, we observed an overlap of more than 2.5% 
between TregN and the memory Treg repertoire (CM or EM) at the applied sequencing depth. 
Only a very small fraction of clones can be found both in the Tconv repertoire as well as in 
the memory Treg (TregCM or TregEM) repertoire (Figure 31A). Furthermore, when we 
search for triple overlapping clones detected in all three Treg subsets (N, CM, EM), there is an 
overlap of around 1.5% between TregN, CM and EM, but almost no triple overlap is found in 
the groups of TregCM, EM and Tconv (Figure 31B). 
  The Morisita-Horn similarity (MH) index is another method to compare two TCR repertoires 
(36, 37). The MH index of the same groups in Figure 31A reveals a significant similarity of 
memory Treg subsets (CM or EM) with TregN, while almost no similarity with Tconv is 
observed (Figure 31C). Alike to the comparison by overlap, the highest similarity is observed 
between TregCM and EM. This data suggests that memory Treg seem to be derived from 
TregN, rather than Tconv. 
  Regarding the highest similarity of TregCM and EM, rank of overlapping clones in the 
repertoires of both populations from one representative donor is shown in Figure 31D. 
Interestingly, these clones are not just top rank ones; instead, they are distributed evenly with 
both high and low frequencies, indicating shared and similar memory development in 
TregCM and EM differentiation phases. Moreover, when we look at the rank of the triple 
overlapping clones in TregN, CM and EM in the CM and EM TCR repertoires, the majority 
of these clones show up around the diagonal, suggesting a similar expansion level in both 
memory phases. However, a small proportion of triplets present in the top ranks of EM, rather 
than CM repertoires, indicating a potentially advanced clonal expansion in EM. However, no 
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significant decreased Shannon entropy was obtained in TregEM compared to TregCM, 
although the tendency was observed (Figure 31E). 
 
Figure 31: Memory Treg seem to be derived from naïve ones rather than Tconv with highest similarity 
between TregCM and TregEM. (A) Intersections of clones between TregCM and EM, memory Treg subset 
(CM or EM) and TregN or Tconv are shown separately as % double overlap in total clones of the latter cell type. 
(B) Triple overlapping clones are still observed in 3 Treg subsets (TregCM / EM / N), but not in the group of 
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 “TregCM / EM / Tconv”. % triple overlap is proportion of shared clones in total clones of the last T cell type. 
(C) Morisita-Horn index of “TregCM / EM”, “Treg (CM, EM) / TregN” and “Treg (CM, EM) / Tconv” reveal 
highest similarity of repertoire of CM and EM, almost no similarity is shown between the repertoires of 
memoryTreg and Tconv. (D) Distribution of double overlapping clones between “TregCM / EM” and triple 
overlapping ones in “TregN / CM / EM” are shown according to their rank in TregCM and TregEM from a 
representative donor. Cross represents shared clones between TregCM and TregEM; cross with a circle 
represents triply the overlapping clone in TregN, CM and EM. (E) Similar SE values of TregCM/EM. (Lei et al. 
in Preparation) 
  Although no similarity was observed between TregM and Tconv TCR repertoire, small 
similarity of the repertoire between TregN and Tconv is found in Figure 32A. Similarly, very 
small amount of overlapped clones (< 0.3%) is also found between TregN and Tconv; 
however, no triple overlap among TregN, TregM and Tconv could be observed (Figure 32B), 
i.e. potential overlap of clones between naïve Treg and Tconv are not detectable in memory 
Treg repertoire, suggesting possible contamination of highly diverse naïve Treg with Tconv by 
sorting. Nevertheless, expanded clones in memory Treg are totally different with Tconv 
repertoire, thus “self-reactive”. In addition, memory Treg repertoire is much more clonal 
expanded than respective memory Tconv due to lower Shannon entropy (Figure 32C).  
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Figure 32: Small overlapped clones between TregN and Tconv were not detectable in more clonal 
expanded TregM. (A) Small similarity of TregN and Tconv was observed. (B) Small double overlapped clones 
were found between TregN and Tconv, but no triple overlap among TregN, TregM and Tconv could be observed. 
(C) Similar clonal diversity of TregN and TconvN, but more clonal expansion in TregM compared to Tconv M. 
(n=8, Wilcoxon matched pairs test). 
  To sum up, the NGS data on TCR repertoires sequences suggest a distinct usage of TCR 
between Treg and Tconv in human. Similar to TconvM, clonal expansion was also observed 
among TregM while TregN showed a polyclonal repertoire (top clones with frequency <1%). 
The strong overlap between TregN and TregCM and even more between TregCM and 
TregEM as well as the absence of overlap between TregCM/EM and Tconv suggest that 
TregM are more likely derived from TregN rather than Tconv (e.g. as so called induced Treg). 
Additionally, diversity of the TCR repertoire of TregM seems to be lower than the respective 
TconvM in human although both naïve repertoires are equally diverse. 
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5. DISCUSSION 
According to the first aim of this study, heterogeneous composition and activation pattern of 
Treg in healthy donors and Tx patients were analyzed. In both cases, Treg population consist 
of naïve (CD45RA+CD62L+), central-memory (CM, CD45RA-CD62L+) and effector-memory 
(EM, CD45RA-CD62L-) sub types although 1.1% of TEMRA (CD45RA
+CD62L-) cells are 
found in Treg form Tx patients. Central memory cells are the majority of Treg in both cases. 
Age and gender have no significant influence on total Treg frequency; however, proportion of 
naïve and CM subsets are affected reversely by age. Furthermore, this subset composition in 
Treg is the same as their counterpart, Tconv; however, their activation patterns are distinct: 
Treg up-regulate only CD137 expression whereas Tconv up-regulate both CD137 and CD154 
upon in vitro upon TCR stimulation. Interestingly, due to long exposure to allo-antigens, Treg 
from Tx patients are pre-activated with CD137 expression in absence of in-vitro stimulation 
and more susceptible to activation induced cell death; together with other observations that 
Treg in Tx patients contain less naïve but more EM cells than age-matched healthy donors; 
these data indicate that Treg in Tx patients are further differentiated and effector-memory 
might be the terminal phase. 
  To the second aim of this work, functional analysis of Treg subsets were performed from 
different aspects and CM was the most efficient phase for Treg to do regulation job. Firstly, 
TregCM showed significantly higher suppression activity in controlling early activation of 
CD4 and CD8 T cells than naïve Treg. In a longer (4 days) proliferation assay, TregN and 
TregCM showed equivalent inhibition to proliferation of non-apoptotic PBMC, but only 
TregCM could induce apoptosis to autologous PBMC whereas TregN could not. Moreover, 
cross-talk between Treg and other immune cells was found as inhibition of proliferation was 
observed from both T cells and non-T cells (mainly NK cells and B cells) and significant 
apoptosis induction was mainly seen on non-T cells. After 3-wk expansion of Treg subsets 
with rapamycin, TregN converted into CM phenotypically with enhanced suppression activity 
whereas most TregCM still stay in CM phase with similar suppression activity and small 
proportion of it diverted into EM phase. Poor expansion of TregEM indicates again the 
possible terminal differentiation phase for EM. These data imply that expansion with total 
Treg is optimal for adoptive Treg therapy as the majority of them belong to highly potent CM 
phenotype; additionally, Treg expansion in a newly developed gas-permeable and GMP-
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compliant rapid culture device, G-Rex10, provides promising prospect for adoptive Treg 
therapy as >50 fold of expansion could be achieved stably by that. 
  To the third aim of this work, the NGS data on TCR repertoires sequences suggest a distinct 
usage of TCR between Treg and Tconv. Similar to TconvM, clonal expansion was also 
observed among TregM while TregN showed a polyclonal repertoire (top clones with 
frequency <1%). The strong overlap between TregN and TregCM and even more between 
TregCM and TregEM as well as the absence of overlap between TregCM/EM and Tconv 
suggest that TregM are more likely derived from TregN rather than Tconv (e.g. as so called 
induced Treg). 
5.1 Phenotypic analysis of Treg from healthy donors and Tx patients  
5.1.1 Similar subsets composition, but more memory cells in Treg than in Tconv 
Regarding Treg subsets composition in peripheral blood, similar to CD4 Tconv, Treg also 
consist of naïve, central-memory and effector memory subsets (10, 11, 38); moreover, each 
subset in Treg was weakly but positively correlated with the same subset in donor-matched 
Tconv, indicating their possible in parallel development, which have been proposed recently 
by Duhen et al. (138). But unlike Tconv (particularly CD8 but also some CD4) (39), no TEMRA 
cells are found in Treg populations from healthy adults as shown in Figure 7G. Furthermore, 
we could show that the majority of memory Treg belongs to the CM phenotype. Although we 
did not find an impact of age or gender on total Treg counts, there is a significant inverse 
relation between loss of TregN and increase of TregM with age as recently described (12, 40, 
41). We could show for the first time that TregCM but not TregEM significantly increase with 
age. Enrichment of TregCM reaches a plateau at the age >40 years, which is similar to the 
very recent publication on total memory Treg by Schlossberger et al. (41). Moreover, 
compared to the respective Tconv, Treg contain much higher frequencies of CM cells. This 
data suggests that memory Treg population development might be the result of (auto) antigen 
exposure during the first decades of age that is obviously stronger than exposure for non-self 
antigens to Tconv. Interestingly, autoimmunity rarely manifests after the age of 50 years, 
suggesting that auto-regulatory processes are decided within the first half of life. In contrast to 
Treg; however, memory Tconv further expand in elderly (>50 years) donors as the result of 
chronic/repetitive non-self antigens exposure. 
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5.1.2 Distinct activation patterns of Treg and Tconv subsets via TCR stimulation 
Regarding the activation pattern, different activation patterns are found in Treg with 
CD137+CD154- cells and Tconv with CD137+CD154+ or CD154+CD137- cells as others have 
reported with antigens stimulation (122). Furthermore, when Treg subsets are included in the 
analysis, more CD137+CD154- cells and less CD137+CD154+ cells are found in TregM than 
TregN. According to the recent publication, CD137+CD154- cells represent an antigen-
reactive Treg population with higher purity due to higher demethylation level than CD154+ 
cells (122). Additionally, CD154 was important for naïve T cells polarization (133) and was 
also regarded as an specific marker for antigen specific Tconv (121). Thus, TregM with higher 
CD137 but no CD154 expression may indicate a pure Treg population while TregN contain 
small proportion of double positive cells, which could be contaminated with some Tconv as 
CD154 works more as an activation marker for Tconv rather than Treg; however, in mice, up-
regulation of CD154 expression and its transduced signals promote FoxP3+ Treg generation 
and development in thymus (134). Therefore, it is possible that the CD154 expression in 
peripheral naïve Treg may have similar effect for FoxP3 induction. Higher expression of 
CD137 in TconvM and TregM might relate with its important role in cell survival, 
proliferation and function in CD4 cells (120). Higher expression of both CD137 and CD154 
in TconvM than TconvN may also indicate the faster and stronger reactivity of TconvM upon 
infections. Moreover, according to what Choi et al. have found, CD137 signaling is required 
to neutralize suppressive function of activated (memory) rather than resting (naïve) Treg 
(135), thus higher expression of this molecule on TregM may relate with their stronger 
suppression as we will discuss later. 
  Helios is another important Treg marker as the transcription factor that binds to FoxP3 
promoter and up-regulate its expression (123). In this study, FoxP3+Helios+ cells show no 
CD154 expression, whereas FoxP3+Helios- cells have around 10% CD154+ cells, indicating 
again they might be “contaminated” with Tconv. These data support that FoxP3+Helios+ cells 
define rather  pure Treg population as a recent publication (136). However, Helios expression 
might not be very stable for Treg as we found later that expanded Treg could lose some of the 
expression, but still keep their suppressive capacity. 
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5.1.3 Treg subsets distribution in Tx patients 
The final goal of this research is to translate Treg “from bench to bedside” especially into 
SOT patients. Therefore, it is important to first study the distribution and characteristics of 
Treg subsets in Tx patients. Our data have shown that Tx patients post above 4 years 
transplantation have slightly increased total Treg proportion than healthy donors, indicating 
tolerance induction to some extent. Less naïve but more EM cells are found in Tx patients 
than age-matched healthy donors with even 1.1% of TEMRA cells (CD45RA
+CD62L-), which 
were only found before in CD8 T cells as the terminal differentiated memory cells and very 
susceptible to apoptosis with high levels of perforin and Fas ligand (137); the increase of 
TEMRA cells in CD8 T cells in Tx patients were even associated with acute kidney rejection 
(138). Therefore, increase of EM cells, even TEMRA cells suggest a further differentiate status 
of Treg in Tx patients due to long term exposure to allo-antigens. 
  Activation patterns of Treg subsets in Tx patients showed that frequency of total Treg 
decreased dramatically upon in vitro stimulation (Figure 14A); while that is not the case in 
healthy donors. When CD137 expression was studied, a pre-activation pattern was found in 
only Treg population rather than respective Tconv population in Tx patients. The early 
activation of Treg in these patients should be result of exposure to allo-antigens; and this pre-
activation may also be required for providing more efficient suppression functionality as we 
find later that Treg do the regulation job more efficiently in the CM phase. Nevertheless, 
together with increased EM cells and presence of few TEMRA cells, pre-activation pattern and 
susceptibility to activation induced cell death of Treg in Tx patients all reveal that these Treg 
are pre-activated, thus prone to exhaustion and apoptosis. These data suggest some potential 
limitations of the Treg from Tx patients in keeping their immune tolerance after 
transplantations. 
  In short, the age-dependent shift to memory Treg from both healthy donors and Tx patients 
raises at least three questions that are of interest for both basic knowledge on Treg biology 
and adoptive Treg therapy in elderly patients as it might be impacted: i) are memory Treg 
(particularly the major fraction of TregCM) comparable to TregN regarding their regulatory 
capacity?; ii) are memory Treg stable after in vitro expansion – a prerequisite for adoptive T 
cell therapy?; iii) are memory Treg derived from TregN or converted Tconv, so called induced 
Treg? Data from this study gives at least partial answers to all three questions in the following 
three parts. 
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5.2 Functional analysis of Treg subsets with potential mechanism 
5.2.1 Enhanced suppression by TregCM and possible differentiation of Treg subsets 
CD69 is one of the earliest activation markers for CD4 and CD8 T cells upon stimulation. 
Once expressed, it works also as a co-stimulatory factor for further activation and 
proliferation. Additionally, CD69 is also expressed by other immune cells like NK cells and B 
cells. Thus, it is an important molecule to study the activation and differentiation status of 
immune cells (139, 140). CD154, another important T cells activation marker (121, 141), 
works as a co-stimulatory molecule of the tumor necrosis factor (TNF) family. It is involved 
in immune responses regarding B cells activation and germinal centre formation; development 
of specific or lineage-committed T cells is also reported to critically depend on CD154 
expression (133). Therefore, monitoring CD69 and CD154 expression can be used as a new 
method to study the early activation status of immune cells (118).  
  The majority of Treg in adult healthy donors belong to the TregCM subset, increasing with 
age up to 40 years but only few cells expressing the TregEM phenotype. Therefore, we 
focused on TregCM functionality but found similarities between the two TregM subsets. 
TregCM showed a stronger expression of FoxP3 and their demethylation level of the FoxP3 
locus (TSDR) was even higher than the one of TregN. Most importantly, they expressed 
significantly stronger suppressive capacity to prevent early activation of Tconv regarding 
CD69 and CD154 expression compared to TregN and similar ability to inhibit proliferation of 
Tconv. Moreover, TregCM but not TregN were able to induce apoptosis of responder cells; 
and the apoptosis mainly occurred in un-proliferating cells rather than proliferating ones, 
indicating that suppression of proliferation and induction of apoptosis in responder cells could 
be two separate suppression mechanisms for Treg and occur in parallel in keeping immune 
homeostasis. 
  Interestingly, similar advantages of DRhiCD45RA- Treg and antigen-specific memory Treg 
suppression were also shown by others very recently (142-144), suggesting memory Treg 
containing stronger suppression activity than naïve ones at least in some aspects.   
5.2.2 Potential mechanism of enhanced suppression activity by memory Treg  
Since central memory is the most efficient phase for Treg to exert their suppression, what is 
the mechanism behind? To this end, cytotoxic T-lymphocyte–associated protein-4 (CTLA-4) 
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expression on naïve and memory Treg was compared and more expression was found on 
TregM. As CTLA-4 competes for B7 family molecules CD80/CD86 and inhibits co-
stimulation of neighboring T cells (145), higher expression of CTLA-4 on TregM should 
contribute partly to the enhanced suppression activity. Besides this, Booth et al. also found 
TregM contained higher expression of CD39 than naïve cells indicating more production of 
adenosine (146). Galectin-1, another suppression mechanism, belongs to galactoside–binding 
proteins family and can function as a key regulator for Treg suppression; expression of this 
molecule on Treg is up-regulated upon TCR stimulation (50). Therefore, expression of 
galectin-1 in TregM should also be higher than TregN, thus contributing to the apoptosis 
induction by TregCM rather than TregN.  
5.2.3 Cross talk of Treg and other immune cells 
Besides inhibition of T cells proliferation, suppression to proliferation of non-T cells is also 
observed in this study, indicating cross talk of Treg and other immune cell as others have 
reported before (71). As the gating in this study was first set mainly on lymphocytes, the non-
T cells (CD3- population) should be mainly NK cells and B cells. In the 6-hour stimulation 
assay, suppression of activation by CD69 expression on these cells is not observed, but in the 
4-day proliferation assay, suppression to the proliferation of CD3- population (NK cells and B 
cells) is observed, which is even stronger than suppression to T cell proliferation. Moreover, 
apoptosis induced by TregCM to total PBMC is mainly seen on this non-T cell part, indicating 
indirectly that NK cells and B cells might be more susceptible than T cells to Treg 
suppression regarding cell proliferation and apoptosis. To confirm this, co-culture of Treg and 
B cells or NK cells directly could be performed with assessment of proliferation and apoptosis 
induction after wards. 
5.3 Expansion of Treg in G-Rex10: New options for clinical translation 
5.3.1 Expansion of Treg subsets in vitro 
To get sufficient number of Treg for adoptive therapy, in vitro expansion is a prerequisite for 
adoptive Treg therapy. Recently, it could be shown by several groups that expansion of human 
nTreg is feasible by cross-linking CD3/CD28 and IL-2 in the presence of the mTOR inhibitor 
to prevent conversion and the loss of regulatory activity (147, 148). Here we could show that 
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TregCM are comparably expanded as TregN. Both subsets kept their regulatory potency and 
FoxP3 expression. Remarkably, almost all TregN switched to the TregCM phenotype by 
expansion and reached comparable regulatory potency, supporting the advantage of the 
TregCM phenotype. Total peripheral naïve T cells were reported to divert completely into 
memory cells after 10 days upon poly-clonal stimulation(124). Additionally, Chai et al. have 
reported before that expanded Treg showed higher suppression than freshly isolated ones 
(149), which could also be explained by enhanced suppression activity of originally naïve 
Treg upon TCR stimulation during expansion. Interestingly, regarding the FoxP3 and Helios 
expression in expanded Treg subsets, naïve Treg kept following both expansion and the 
switch to the TregCM phenotype while TregCM kept the TregCM phenotype as well as the 
FoxP3 expression, but lost >50% of the Helios expression, suggesting a rather moderate 
stability of TregCM upon stimulation since Helios binds to the FoxP3 promoter and up-
regulates its expression (123). However, these expanded TregCM still showed equivalent 
suppressive activity as Du et al.. have also reported recently (150), suggesting Helios 
expression for Treg suppressive capacity might not be as important as it is for FoxP3 up-
regulation and Treg stability (123, 151).  
  A smaller proportion of TregN and TregCM also switch to CD45RA-CD62L-(EM) after 3-wk 
expansion. Due to poor proliferative capacity and inefficiency of CD4+CD25hiCD62L- cells in 
protecting from lethal acute graft-versus-host disease (GvHD) in vivo (152), EM might be the 
terminal differentiation stage for Treg. More discussion on the subsets differentiation will 
continue in next part together with TCR repertoire data. 
5.3.2 Expansion of Treg in G-Rex10 device 
Expansion of Treg with rapamycin could keep most of the Treg phenotype and suppression 
function in our hands. However, limited expansion fold is always a big challenge for Treg 
therapy. Using the newly developed cell culture device, G-Rex10, could enhance the 
expansion to at least 50 fold stably without losing phenotype and suppression function. 
Chakraborty et al. have also reported recently that expanded Treg with G-Rex device could 
suppress division of CD8 T cells in vitro and GvHD in vivo in a mouse model (153). Together 
with the GMP compliancy of this air permeable cell culture device, expansion of Treg in G-
Rex will facilitate clinical translation of Treg therapy without doubt. 
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5.4 TCR repertoire analysis 
To answer the third question if memory Treg derived from TregN or converted from Tconv 
like induced Treg, TCR repertoire analysis of Treg and Tconv was performed. Conventional 
tools to do this are mainly focused on CDR3 length distribution rather than real sequence 
analysis. Development of next-generation sequencing (NGS) technology makes the repertoire 
analysis at sequence level achievable. In this study, analysis of repertoire from Treg and 
Tconv subsets from 10 donors shed some light on differentiation relation of these cells during 
thymus and peripheral development. 
5.4.1 Treg M derived from naïve Treg with clonal expansion 
First of all, an average of 660,000 reads was obtained from each sample by NGS technology. 
These data revealed further clonal expansion in memory Treg compared to naïve ones with 
enhanced frequencies of the clones. Due to the influence of different sample size, Shannon 
Entropy (SE) was used to access the diversity of the repertoires in sense of how flat versus 
oligoclonal the clone type distribution was. Significantly decreased SE value in TregM than 
TregN reveals oligo-clonal distribution in TregM at a statistical level. However, to focus on 
each specific clone defined by same CDR3 sequence and V, J genes, clonal expansion of same 
clone in both naïve and memory populations was showed and the highest expansion of one 
clone from naïve to memory Treg reached 500 fold in peripheral blood, which was showed for 
the first time in human. 
  Besides highest expanded clones in the overlap between two population repertoires, 
proportion of total overlap between different populations also support that TregM contain 
significantly higher overlap of the repertoire with TregN than Tconv. However, this is only 
proportion of absolute overlap; taking the possible influence from different sample sizes into 
consideration, the MH index 6  was applied with more statistical relevance. Similarly 
significant higher similarity was found in the group of “TregM / TregN” than the group of 
“TregM / Tconv”, indicating once more memory Treg should derive from naïve ones rather 
than Tconv. 
                                               
6 MH index: Morisita-Horn similarity index 
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5.4.2 Highest similarity of TCR repertoire between TregCM/EM 
However, in both comparison of overlap and MH index, highest overlap and similarity was 
found between Treg CM and EM. Although higher clonal expansion in TregEM was found 
than TregCM in Figure 30A, when we tried to analyze that in a more statistical way with 
Shannon entropy, no significant difference was found although reduced SE was observed in 3 
of the total 4 donors (Figure 31E). However, it should be noted that we calculate the SE value 
by strictly defining each clone containing exactly same V-gene, J-gene and a.a. sequence7; 
significantly reduced SE in TregEM repertoire would be observed compared to TregCM (data 
not shown) if we used the SE value provided by Adaptive Biotechnologies (USA), which was 
computed based on all detected clones without excluding those sequences containing 
“undefined” V-gene or J-gene. To be on the safe side, the former computation was applied in 
this study. 
  In addition, rank of shared clones in Treg CM and EM are evenly distributed with both high 
and low frequencies. However, rank of the triple overlap of TregN, CM and EM show that 
they are not only clones with similar rank in both CM and EM (clones around the diagonal in 
Figure 31D) , but also clones with high rank in TregEM. All of these indicate Treg EM could 
be the possible terminal phase for Treg differentiation with highest clone expansion; however, 
due to the largely distributed shared clones between TregCM and EM, we still could not 
exclude the possible turnover between them. 
5.4.3 TCR Repertoire of human Treg and Tconv 
As the distinct TCR repertoire between TregM and Tconv in human have been clarified 
before, the TregN repertoire was also compared with Tconv and very slight overlap was 
found, i.e. < 0.3% Tconv repertoire were overlapped in TregN repertoire (Figure 32); 
however, these overlapped clones were not expanded or detected in TregM repertoire (Figure 
32B). Thus, the small overlap between TregN and Tconv could be explained to potential 
sorting contaminations as TregN have lower CD25 expression or to the very high diversity of 
TregN repertoire and sensitivity of NGS technology. Nevertheless, as majority of human Treg 
population express memory phenotype, these NGS data suggest a distinct usage of TCR 
                                               
7 a.a. sequence: amino acid sequence 
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between Treg and Tconv in human, which is in agreement with the similar data in mice (106, 
107, 154) and in human by other methods (110). 
  Regarding clonal diversity revealed by Shannon entropy, similar diversity was found 
between TregN and TconvN repertoire as other authors have speculated and showed before 
(155-157). However, when the TCR repertoire of TregM and TconvM were compared, 
significantly reduced diversity was found in TregM repertoire, indicating their advanced 
clonal expansion than donor-matched TconvM repertoire. To our knowledge, this is revealed 
in human for the first time. However, the limited repertoire of TregM might have an impact on 
the efficacy of polyclonal Treg therapy, particularly in elderly patients, as target specificities 
(allo, auto) might be missing 
  From the methodological aspect, the adoption of Shannon entropy and MH index in the TCR 
repertoire analysis shed light on the relevance at a statistical level. The analysis of 
overlapping clonotypes as function of ranks can provide even more hints on relations between 
different sub-population.  
  To sum up, from the first part of the results, heterogeneous composition of Treg with N, CM, 
EM subsets were found in both healthy donors and Tx patients. The age-dependent shift from 
TregN to TregM was mainly occurring into CM rather than EM phase before 40 years old and 
Treg contained significantly higher CM than respective Tconv, indicating memory Treg 
development might be the result of (auto) antigen exposure during the first decades of age that 
was obviously stronger than exposure for non-self antigens to Tconv. Treg from Tx patients 
were even more activated with expressing CD137 and contained more EM cells; furthermore, 
they were susceptible to activation induced cell death, suggesting the limitations of these cells 
in keeping immune tolerance. 
  The second part of the data indicated that TregCM contained enhanced suppression activity 
than TregN in controlling an early activation of T cells and inducing apoptosis to both T cells 
and non-T cells, which may relate with cell-cell contact suppression. For clinical translation, 
expansion of Treg with rapamycin in the air permeable and GMP compliant device, G-Rex10, 
significantly increased the expansion fold to 50 stably without losing Treg phenotype and 
function. Following in vitro expansion of subsets, the majority of TregN switch to TregCM 
phenotype associated with enhanced suppressive capacity to the level of TregCM, indicating 
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expansion of total Treg are optimal for Treg therapy as majority of them express CM 
phenotype. Poor proliferation of TregEM hinted the terminal differentiation stage. 
  Lastly, TCR repertoire data from NGS suggest that TregM derived from naïve one rather 
than Tconv with highest clonal expansion of 500 fold in an antigen-driven process. Highest 
similarity was found between TregCM and EM. However, the limited repertoire of TregM 
might have an impact on the efficacy of polyclonal Treg therapy, particularly in elderly 
patients, as target specificities (allo, auto) might be missing. 
  In short, these data shed some light on human Treg subsets distribution, functionality and 
differentiation. The enhanced suppressive capacity of freshly isolated TregCM and the 
stability after expansion have significant importance for clinical translation of adoptive Treg 
therapy, implying that expansion with total Treg is optimal for adoptive Treg therapy since the 
majority of them belong to CM phenotype. From the basic immunological aspect, these data 
shows for the first time that peripheral human Treg M derive from naïve ones rather than 
Tconv with the highest similarity found between CM and EM repertoires and TregEM might 
be the terminal differential phase. 
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